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ABSTRACT 
The focus of this thesis was to study the chemotaxonomic relationship of selected 
southern Australian marine brown algae of the genera Cystophora and Sargassum. 
Consequently, this resulted in the isolation and structure elucidation of six new terpenoids 
from two southern Australian marine brown algae Cystophora moniliformis and Sargassum 
fallax together with 10 previously reported natural products. As a result of the re-isolation 
of these known secondary metabolites, updated and complete structural characterisation 
data could be provided for the first time for 7 of these compounds.  
Chemotaxonomic studies of Cystophora moniliformis resulted in the isolation of two 
new cyclic epimeric terpene diols moniliforminol A (3.25) and moniliforminol B (3.26), a 
new linear farnesyl acetone derivative (3.27) and the previously described terpenoids 
(3.19)-(3.24). This study also resulted in the first complete 2D NMR characterisation for 
compounds (3.21) to (3.24) as well as the first report of (3.24) occurring as a natural 
product. All structures were elucidated by detailed spectroscopic analysis with the relative 
configurations of (3.25) and (3.26) being established by selective 1D nOe NMR 
experiments. The proposed biosynthetic pathway for the above compounds has also been 
described. 
Chemical investigation of the Southern Australian marine brown alga Sargassum fallax 
resulted in the isolation of three new meroditerpenoids fallahydroquinone (4.8), 
fallaquinone (4.9) and fallachromenoic acid (4.10), together with the previously reported 
compounds sargaquinone (4.1) (isolated and identified in a mixture with sargaquinoic 
acid), sargahydroquinoic acid (4.2), sargaquinoic acid (4.3) and sargachromenol (4.11). As 
a result of this study the complete 2D NMR characterisation for sargahydroquinoic acid 
(4.2) and sargaquinoic acid (4.3) could also be reported for the first time. All structures 
were elucidated by detailed spectroscopic analysis. Sargahydroquinoic acid (4.2) and 
sargaquinoic acid (4.3) displayed moderate antitumour activity. 
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1. Introduction 
1.1 Background 
The importance and use of natural products predominantly originated from the use of 
plants, which formed the basis of sophisticated traditional medicine systems that have been 
in existence for thousands of years.1,2 Egyptian medicine dates back to as early as ~2900 
BC with the most recognised ancient Egyptian pharmaceutical record, known as the Ebers 
Papyrus, dating from 1500 BC.1,2  
In contrast to terrestrial plants, marine organisms do not have any significant 
ethnobotanical history.1 However, the exploitation of the marine environment as a source 
of new and bioactive secondary metabolites became inevitable. Biodiversity (or species 
diversity) is vital in the search for new chemical entities in drug discovery research. With 
seventy percent of the earth’s surface being covered by water, some oceans exceeding 
3000 metres in depth and the existence of hydrothermal vents and seamounts, the 
biodiversity that exists in the marine environment is unsurpassed. In the quest for new 
drugs, humankind has only explored a small portion of this complex ocean. Of the 33 
animal phyla listed by Margulis and Schwartz, 32 are represented in aquatic environments, 
with 15 being exclusively marine, another 17 being marine and non-marine (five of these 
having >95% of their species only found in marine environments), and only one, 
Onychophora, being exclusively non-marine.1  
Natural product research can be constrained by the available sample collection methods.3 
Initially SCUBA technology provided access to depths of approximately 3-35 metres, 
which was a major improvement to the collection of marine organisms by skin diving.1 
Further improvements led to the development of closed circuit underwater breathing 
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apparatus (CCUBA), which allows the exploration of underwater environments as deep as 
150 metres as well as extended bottom time.3 As an example of the use of this technology, 
the deep-water collection of Myrmekioderma styx could be achieved and resulted in the 
isolation of >30 new sesquiterpenes and diterpenes from this individual sponge.4 In 
addition to CCUBA, exploration of deep-sea environments is now possible using remotely 
operating vehicles (ROVs). The use of ROVs enabled deep-sea collection of the jellyfish 
Bumpy (Stellamedusa ventana) and the eel-like halosaurs from the eastern Pacific Ocean.3  
This thesis provides an up-to-date review of the most promising biologically active 
marine natural products being developed as potential leads in the pharmaceutical industry. 
In addition, due to the extensive studies conducted on marine brown algae in this thesis, a 
review of the new secondary metabolites reported from brown algae between the years 
2003 and 2008, including associated biological activities, is also provided. Emphasis is 
placed on the complexity of the natural products produced by the Cystophora and 
Sargassum spp. and their contribution towards chemotaxonomy is discussed. 
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1.2 Historical Drug Discovery in Plants 
As already mentioned, constituents derived from plants provided most of the earlier 
pharmacologically active natural products.5 Some well-known examples of drugs of plant 
origin include the antimalarial agent quinine from the bark of Cinchona officinalis 
(Rubiaceae), the analgesics codeine and morphine from Papaver sonniferum 
(Papaveraceae), atropine from Atropa belladonna and other Solanaceae species, and the 
cardiac glycoside digoxin from Digitalis sp. (Scrophulariaaceae).5 The diterpenoid 
paclitaxel (previously known as taxol) isolated from the bark of the Pacific yew Taxus 
brevifolia (Taxaceae) in the late 1960s, has been used for the treatment of ovarian cancer 
resistant to chemotherapy and its therapeutic applications have also been applied in relation 
to other gynaecologic cancers.5 
The potential for higher plants as sources for new drugs still remains largely unexplored. 
Among the estimated 400,000-500,000 plant species worldwide, only a small percentage 
had been investigated phytochemically and an even smaller fraction has been submitted to 
biological or pharmacological screening.5 
The current influence of plant-derived medicine is substantial. For example, an analysis 
of the data on prescriptions dispensed from community pharmacies in the United States 
(US) from 1959 to 1980 indicated that about 25% of these contained plant extracts or 
active principles derived from higher plants.1 A more recent study using US-based 
prescription data from 1993 indicated that natural products from all sources were still 
playing a major role in drug treatment and that >50% of the most-prescribed drugs in the 
US had a natural product origin, either as the drug itself or as a model in the synthesis or 
design of the agent.1  
Nature continues to be a source of potential chemotherapeutic agents, as reported and 
reviewed by Newman et al (see Figure 1.1).1,6 Using the definitions provided in Figure 
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1.1, the sources of new drugs over the period 1981-20051,7 indicate that although 66% of 
the 955 small molecule new chemical entities are formally synthetic, 17% are synthetic 
molecules containing pharmacophores derived directly from natural products, with 12% of 
the remainder being either modeled on or mimicking a natural product. Thus, only 37% of 
the 955 new chemical entities can be classified as truly synthetic in origin. 
 
 
Percentages, small molecules, all categories, N = 955 
S
37%
ND
28%
N
6%
S*/NM
12%
S*
5% S/NM
12%
 
N  Natural Product 
ND  Derived from a natural product (usually a semi-synthetic modification) 
S  Totally synthetic drug, often found by random screening/modification of an existing agent 
S*  Made by total synthesis, but the pharmacophore is/was from a natural product 
NM Natural product mimic “designed from knowledge gained from a natural product”  
 
Figure 1.1 Sources of new chemical entities, 1981-2005 (Adapted from Cragg and 
Newman, 2008).1  
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1.3 Anticancer agents from marine sources 
The focus of the development of marine natural products as potential drugs has been 
vastly in the area of anti-cancer agents. There are many marine-derived agents that have 
previously been or are currently, the subject of clinical trials for the treatment of cancer. As 
yet, none has reached the stage of commercialisation.  
The initial discoveries from the marine environment can be traced to the 1950s from 
reports by Bergmann,8-10 who discovered and subsequently identified spongothymidine 
(1.1) and spongouridine (1.2) in the early 1950s from the Caribbean sponge Tethya crypta. 
The discovery of these biologically active arabinose nucleosides led to the demise of the 
then current theory that for a nucleoside to have biological activity, it had to have ribose or 
deoxyribose as the sugar.8-10  
HN
N
O
O
HN
N
O
O
(1.1) (1.2)
O
HO
HO
OH
O
HO
HO
OH
 
1.3.1 Marine-Derived Agents Currently in Clinical Trials 
Bryostatin 1 (1.3) is a macrocyclic lactone isolated from the bryozoan Bugula neritina 
in minute yields. Bugula neritina is quite ubiquitous, however the colonies that produce 
bryostatin 1 and analogues bryostatins 2 & 3 are rare and geographically dispersed.11 It has 
therefore been proposed that the bryozoan is actually the host to a symbiotic micro-
organism that may well be the actual source of the compound.11 Bryostatin 1 is currently in 
phase II clinical trials for anticancer treatment.1,12 It has been found that its use as a single 
agent is probably not the optimal application for this compound: it is more efficient in the 
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treatment of carcinomas that are leukemic in nature when combined with cytotoxins, such 
as the vinca alkaloids or nucleosides.11  
O
O OHO
O
COOMe
O
O OH
H
HO
O
O
HO
O
COOMe
H H
H
(1.3)  
Dolostatin 10 (1.4) is a linear member of a series of cytotoxic peptides that were 
originally isolated in very low yields from the Indian Ocean mollusc Dolabella 
auricularia.1,11 Although it was terminated from clinical trials in the year 2000, several of 
its analogues are currently in clinical development.1 
 
NH
N
N
OO
NHN
O
OO O
H
(1.4)
S
N
H H H
 
In 2004 the dolostatin derivative, TZT-1027 (auristatin PE or soblidotin) (1.5) was in 
Phase I clinical trials in Europe, Japan, and the United States under the auspices of either 
Teikoku Hormone, the originator, or the licensee, Daiichi Pharmaceuticals.11 Since then 
TZT-1027 has progressed to phase II clinical trials and has been shown to exhibit potent 
antivascular effects in addition to antitubulin activity, suggesting that a dual mechanism 
may be operating for this compound.1,13,14  
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Similar progress took place with the Dolastatin analogue cematodin (LU-103793) (1.6) 
currently in phase II clinical trials against malignant melanoma, metastic breast cancer, and 
non-small cell lung cancer.1 The activities reported include stabilisation of the diseases 
melanoma and breast cancer and as for the lung trials, a subjective increase in the quality 
of life was measured.1,15-17  
The final dolastatin 
analogue that progressed to 
phase II clinical trials was 
ILX651 (synthadotin or 
tasidotin) and also initiated 
studies in melanoma, breast and non-small cell lung cancers. This third-generation 
analogue of dolastatin 15 displays activity when administered 
orally as well.1,18-20  
 
Ecteinascidin 743 (ET743; Yondelis™) (1.7) was originally 
isolated in very low yields from the ascidian Ecteinascidia 
turbinata.21,22 Ecteinascidin 743 is currently the subject of a 
number of phase II/III clinical trials for ovarian, soft tissue 
sarcoma, breast, endometrial, prostate, non-small cell lung, 
and paediatric cancers, and has been granted orphan drug (a pharmaceutical agent that has 
been developed specifically to treat a rare medical condition, the condition itself being 
NH
N
N
OO
N
H
N
O
OO O
H
H H
(1.6)
H
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referred to as an orphan disease) status by the European Commission for soft tissue 
sarcoma and ovarian cancer.1 Ecteinascidin 743 is the first of a novel class of DNA-
binding agents exhibiting a complex, transcription-targeted mechanism of action.1,11 If 
approved for marketing, it will be the first, direct-from-sea, antitumour agent to reach 
commercialisation.1,11 
 
Aplidine (dehydrodidemnin B) (1.8) is a 
depsipeptide was from the Mediterranean 
tunicate Aplidium albicans. In 1999 it 
progressed from phase I to phase II clinical 
trials for cancers including melanoma, 
pancreatic, head and neck, small cell and non-
small cell lung, bladder, and prostate cancers, 
as well as non-Hodgkin lymphoma and acute lymphoblastic leukemia.1 
 
A synthetic analogue of halichondrin B (1.9), E7389 (1.10), is now in phase III clinical 
trials, particularly against 
refractory breast carcinoma.1 
Halichondrin B (1.9) was 
isolated from several sponges, 
including Halichondira okadai 
from Japan), an Axinella sp. 
from the Western Pacific, Phakellia carteri from the Eastern Indian Ocean, and a deep 
water Lissodendoryx sp. off the East Coast of the South Island of New Zealand.1 The 
O
O
O
NH
O
N
N
H
N
O
N
O
O
O
HO
O
O
NHO
O
(1.8)
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synthetic strategy used to synthesise halichondrin B (1.9) was adopted for the synthesis of 
a large number of structurally simpler analogues including E7389 (1.10).1,23  
O O
H
O
H
HH HHO
H
O
H
H H
O O
H
O
H
O
O
H2N
OH
(1.10)  
Kahalalide F (1.11) was isolated 
from the Sacoglossan mollusc 
Elysia rufescens.  This compound 
originates from the green 
macroalga, Bryopsis pennata, on 
which the mollusc grazes.24,25 In 
December 2000 it reached phase I 
clinical trials in Europe for the 
treatment of androgen-independent 
prostrate cancer.1  
 
 
Synthetic analogue 7974 (1.12) of hemiasterlin, 
which was isolated from the South African sponge 
Hemiasterella minor and shortly thereafter from a 
Papua New Guinea sponge Cymbastela sp is currently 
in phase I clinical trials. Unfortunately a large number of hemiasterlin synthetic analogues, 
including the most effective HTI-286, were suspended at the phase I clinical trial stage.1  
N
N
H
N
O
OH
O
(1.12)
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KRN-7000 (1.13), one of the various synthetic 
analogues of the agelasphins, obtained from the 
marine sponge Agelas mauritianus, is in phase I 
clinical trials in the area of cancer immunotherapy.1 
Squalamine (1.14), isolated from the common 
dogfish shark, Squalus acanthias and collected off the 
New England coast, is a simple aminosterol with 
broad-spectrum antibiotic activity, but was also found 
to exhibit significant antiangiogenic activity.1 The 
most recent reports describe the activity of squalamine (1.14) in the treatment of wet 
macular degeneration, where significant activity is now being seen and phase III trials are 
underway. Its antiangiogenic activity is exploited to stop the unrestrained capillary growth 
that is the underlying cause of this disease.1 
Neovastat (AE-941) is a protein liquid extract from the cartilage of certain shark 
species.1 The most recent report states that it is in a long-term phase III trial for the 
treatment of non-small cell lung carcinoma.1  
O
O
(CH2)13CH3
NH
O
(CH2)24CH3
OH
OH
HO
HO
OHOH
OH
(1.13)
OSO3H
H
HN H
N
NH2
OH
(1.14)
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1.4 New Brown Algae Secondary Metabolites Reported from 2003 to 2008 
Terpenes and acetogenins have been the most frequently reported structural classes from 
brown algae.26-32 Terpenes are several isoprene units combined together and acetogenins 
are polyketides derived from acetate units. The occurrence or even absence of these 
compounds in species has been proposed as an interesting tool for identification of algae 
within a genus. 26-32   
The presence of acetogenins has been suggested to be indicative of a less advanced 
secondary metabolism whilst the increasing complexity of terpenes is believed to reflect a 
rising sophistication in secondary metabolism.33 Amico and coauthors contend that the 
presence of terpenes and their increasing complexity is indicative of advancement, placing 
it higher in the phylogenetic tree.33 This important phytochemical inference has been 
adopted when addressing chemotaxonomy in subsequent literature on brown algae (class: 
Phaeophyceaeae).38 Therefore, knowledge of the phytochemistry of the organism can be 
used with morphology to help identify species within genera.33 This would overcome the 
many difficulties encountered when identifying species based purely on morphology.33 
Chemotaxonomic studies of various structural classes of brown algae have been detailed 
by Amico et al.33 The secondary metabolites isolated from the Cystoseira genus were 
categorised and defined as intra-generic taxonomic markers. Preliminary classifications 
were also attempted for other genera based on distinctive structural aspects and 
inferences.33  
Consequently, in this Chapter a preliminary attempt will be made to generalise some 
classes of compounds produced by the most studied brown algae reported between the 
years 2003 to 2008 followed by examples of other genera, which have been reported to a 
lesser extent during this period. Some structural classes that are mentioned in this review 
include meroditerpenoids, which consist of a polyprenyl chain (terpene chain) attached to a 
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hydroquinone ring moiety. Meroditerpenoids have a mixed biogenesis, the precursor of 
linear diterpene chain is geranylgeraniol and the precursor of the aromatic moiety is 
shikimic acid. They can be divided into four classes according to the nature of the side 
chain, namely linear, monocyclic, bicyclic or rearranged. Other sub-classifications include 
plastoquinones, chromanols and chromenes, distinguished mostly in the aromatic moiety as 
shown in Figure 1.2.  
O O
HO HO
O
O
Chromene Chromanol
Plastoquinone  
Figure 1.2. The general classes of meroditerpenoids include chromenes, chromanols and 
plastoquinones, which as illustrated, differ mostly in the aromatic moiety. 
 
General classes of compounds, which have been shown to be influenced by geographical 
locations, are also listed. For example, the brown alga, Stypopodium zonale has shown 
chemical variation in different geographical locations, along with morphological 
differences.34 In addition, all significant biological activities displayed by compounds 
produced by members of different genera will be provided in the review. 
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1.4.1 Sargassum species  
Sargassum carpophyllum, from the South China 
Sea, was the source of two biologically active sterols 
(1.15) and (1.16).28 These sterols induced 
morphological abnormality in the plant pathogenic 
fungus Pyricularia oryzae and compound (1.15) also 
exhibited cytotoxic activity against several cultured 
cancer cell lines.28 Subsequently reported by the same 
group (Tang et. al), was the isolation of a novel steroid 
(1.17), also from S. carpophyllum from South China 
Sea.29 It is unclear whether (1.17) was obtained from 
the same sample as (1.15) and (1.16).  
The sterol stigmast-5,23,25-triene (1.18) was 
isolated from S. polycystum, collected in the North 
China Sea 28 and S. asperfolium, collected in the Suez 
Gulf, was the source of the steroidal metabolite 
saringosterone (1.19).29  
S. parvivesiculosum (Hainan Province, China), 
yielded two glycerol derivatives (1.20) and (1.21).30  
O
O
OH
(1.20)
O
OH
O
*
25
OH
(1.21)
OH
OH
O
O
OH
(1.15)
(1.16)
O
H
EtOOC OH
H H
(1.17)
OH
(1.18)
OH
H
H H
O
(1.19)
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OH
O
(1.23)
O OH
(1.25)
The sterol secondary metabolites produced by S. carpophyllum, S. polycystum, S. 
asperfolium and S. parvivesiculosum are classified as acetogenins, which suggests a less 
advanced secondary metabolism. However since re-isolated known compounds are seldom 
reported in literature it is difficult to assemble a truly comprehensive data of secondary 
metabolites in these organisms and thus make conclusions about their position 
phylogenetically.  
The brown alga S. crispum, collected from the Red Sea, was 
the source of sargassinone (1.22),31 which has a structural 
skeleton reminiscent of a terpenoid origin.  
The hedaols A–C (1.23–1.25) are simple linear 
chain terpenoids, which were isolated from the 
Japanese brown alga Sargassum sp. (unidentified 
species). The compounds displayed weak 
cytotoxicity (to P388 cells).31 
S. siliquastrum (Jaeju Island, Korea), yielded 
meroditerpenoids of the chromene class, namely 
sargachromanols A-P (1.26)-(1.41).26  
S. micracanthum (Toyama Bay, Japan), yielded the known compounds (1.42) and (1.43) 
and was the source of strongly antioxidant plastoquinones (1.44)-(1.47), three of which 
(1.45)-(1.47) also showed antiproliferative effects against 26-L5 cells.26  
 
 
H
H
O
HO
(1.22)
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O R
HO
(1.26) R = CHO
(1.27) R = CH2OH
O
HO
OR1
R2 R3
(1.28) (9'R) R1 = R2 = R3 = H
(1.29) (9'R) R1 = R3 = H, R2 = OH
(1.30) (9'R) R1 = R2 = H, R3 = OH
(1.31) R1 = Me,  R2 = OH, R3 = H
(1.36) (9'R) R1 = H, R2 = R3 = O
O
HO
O
OH
(1.32) (10'R)
(1.34) (10'R)     saturated
(1.35) (10'S)     saturated
10' O
HO
CHO
8'
(1.38) (8'E)
(1.39) (8'Z)
9'
O
HO
O
OH
(1.33)
O
HO
R
(1.37) R = CH2OH
(1.40) R = COOH
O
HO
O
(1.41)
     
R
OH
OH
(1.42) R =
HO
OH O
O
(1.43) R =
 
R
OH
O
(1.45) R =
O
O
(1.44) R =
HO
OH
 
OH
OH
OH
O
O
5
7
(1.46)     saturated
(1.47)
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S. thunbergii (Busan, Korea), yielded the tetraprenyltoluquinols, thunbergols A (1.48) 
and B (1.49), which were shown to act as scavengers of the DPPH radical and of ONOO- 
from morpholinosydnonimine (SIN-1).27 
O
COOH
OHHO
(1.48)
O
COOH
HO
HO
(1.49)  
1.4.2 Dictyopteris species  
Dictyopteris species have been reported to produce 
predominantly relatively complex sesquiterpenes (C15 unit or 
three isoprene units). Dictyopteris undulata yielded a 
sesquiterpene benzoquinone (-)-cyclozonarone (1.50).31 The 
absolute configuration (5R, 10R) of the naturally occurring (-)-
cyclozonarone was established by comparison 
with the optical rotation and spectral data of its 
synthesised form, which is also reported to be 
the first enantiospecific synthesis that has been achieved. Polygodial was utilised as the 
starting material.31 Another Dictyopteris undulata specimen from 
Japan, produced the meroditerpenoid, dictyochromenol (1.51).28 
Dictyopteris divaricata (Shandong coast, China), yielded a 
sesquiterpene-substituted benzoic acid, dictyvaric acid (1.52).30 
O
HO
(1.51)
H
OH
COOH
HO
(1.52)
O
O
H
(1.50)
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Three different samples of D. divaricata were independently reported from the Qingdao 
coast, China and yielded different sub-classes of sesquiterpenes. One sample produced 
seven cadinane sesquiterpenes, (1.53)-(1.59),30 the second sample was the source of the 
R
H
OH
(1.53) R = O
(1.54) R = αH, βOH
(1.55) R = βH, αOH
OH
R1
R2
(1.56) R1 = H, R2 βOH
(1.57) R1 = OH, R2 αOH
OH
H
OH
OH
OH
H
CHO
(1.58) (1.59)
 
 bisnorsesquiterpenes (1.60)-(1.62) and the norsesquiterpene (1.63)26 and the third 
sample was the source of five sesquiterpenes (1.64)-(1.68) possessing new carbon  
O
R
(1.60) R = βOH
(1.61) R = αOH  
O
OH
(1.62)  
O
H
(1.63)  
skeletons. The  third sample also yielded an oplopane sesquiterpene (1.69).27  
O
H
OH
(1.64)
O
H
OH
OH
(1.65)
O
H
OH
OH
(1.66)
  
OH
O
OH
(1.67)
O
O
OH
(1.68)
O
O
OH
(1.69)
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O
OHO
OH
(1.71)
O
O
OH
(1.72)
O
OH
R1
HO
OH
OH
R2
(1.73) R1 = H, R2 = Me
(1.74) R1 = OH, R2 = CH2OH
OH
OH
R OH
(1.75) R = Me
(1.76) R = OAc
1.4.3 Dictyota species 
Dictyota dichomota, collected from the Red Sea, afforded 
the terpenoids the known compound dictyone acetate and a 
pachydictyol A derivative (1.70).29 D. dichotoma from the 
Arabian sea produced structurally similar compounds 
including two seco-dolastanes, dichotone (1.71) and dichotodione (1.72), two dolastane 
diterpenoids, dichototetraol (1.73) 
and dichopentaol (1.74), and two 
dolastane diterpenoids, 
dichotenones A (1.75) and B 
(1.76).29 D. dichotoma from the 
Karachi coast of the Arabian Sea 
yielded three seco-dolastanes 
sharing the same carbon skeleton, 
dichotenols A-C (1.77)- (1.79).30 
D. dichotom  a, from the Aegan 
Sea, yielded a new diterpene 
with a similar structural 
skeleton, isopachydictyolal 
(1.80).30 Yet another sample of 
D. dichotoma (origin not 
reported) yielded a rare 
chlorine-containing 
perhydroazulene diterpene, 
dictyol J (1.81), along with two known diterpenes, dictyolactone and sanadaol.27 From D. 
H
H
OH H
(1.70)
OH
O
CHO
OH
H
H
(1.80)
O
OAc
R
OHO
O
OH
O
O
OH
(1.77) R = H
(1.78) R = OH
(1.79)
OH
ClH
H
H
(1.81)
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(1.82)
H
H H
(1.83)
dichotoma (Troitsa Bay, Sea of Japan), two new diterpenes, ent-erogorgiaene (1.82) and 
(+)-1,5-cyclo-5,8,9,10-tetrahydroerogorgiaene (1.83), were characterised.27  
It can be inferred that the classes of compounds produced by 
the species Dictoyta dichotoma do not vastly differ upon 
geographic location except for the species that was located 
in Troitsa Bay, Sea of Japan. 
D. crenulate, collected from Easter Island, produced the new diterpene, dictyocrenulol 
(1.84).29  
Chemical investigation of D. linearis (Chios Is. Greece) 
resulted in the isolation of 4a-acetyldictyodial (1.85).  
D. pfaffi (Northeast Brazil), resulted in the isolation of a 
new dolabelladiene derivative (1.86) as well as the 
previously isolated 10,18-diacetoxy-8-hydroxy-2,6-
dolabelladiene.30 Both compounds showed strong anti-
HSV-1 activity in vitro but little inhibition of HIV-1 
reverse transcriptase.30 10,18-Diacetoxy-8-hydroxy-2,6-
dolabelladiene was identified as the antifeedant component 
of D. pfaffi, deterring the sea urchin Lytechinus variegatus 
as well as fish in general.30  
 
Dictyota species appear to be a source of a range of unique complex diterpenoids. 
However, further study would be required to understand trends and patterns in structural 
classes produced within each species. It appears in this preliminary investigation that there 
are differences observed in the classes of compounds produced between species such as D. 
dichotoma and D. linearis.               
OAc
OAc
H
OH
(1.84)
OAc
CHO
OHC
(1.85)
H
HO
AcO
HO
(1.86)
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1.4.4 Cystoseira species 
The Cystoseira genus, which is the most advanced member of its family 
(Cystoseiraceae), is known to produce a range of relatively complex meroditerpenoids.33 
From Cystoseira crinite, collected from the South Coast of Sardinia, six 
tetraprenyltoluquinols (1.87)- (1.92), two triprenyltoluquinols (1.93) and (1.94) and two 
tetraprenyltoluquinones (1.95) and (1.96) were isolated.29 All compounds were tested for 
antioxidative properties in the DPPH and TBARS assay systems. Compounds (1.87)-(1.94)  
R1 R2OOH
OH
(1.87) R1 = H, R2 = CH2OH
(1.88) R1 = OH, R2 = Me
(1.89) R1 = H, R2 = Me  
OH
OH
(1.93) (6'E)
(1.94) (6'Z)  
O
OH
OH
R1 R2
(1.90) R1 = H, R2 = CH2OH
(1.91) R1 = OH, R2 = Me
(1.92) R1 = H, R2 = Me
OOH
OH
(1.95) (6'E)
(1.96) (6'Z)
O
 
exhibited potent radical scavenging effects, while (1.95) and (1.96) were significantly 
less active, but still comparable to that of BHT.29 The radical scavenging activity of 
compounds (1.91), (1.92) and (1.96) was further assessed using TEAC and PCL assays that 
confirmed their potent radical scavenging ability.29 Compounds (1.187) and (1.190) were 
moderately cytotoxic against several carcinoma cell lines.29 
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Cystoseira myrica, collected in the Gulf of Suez, yielded four hydroazulene diterpenes, 
dictyone acetate (1.97), 
dictyol F monoacetate 
(1.98), isodictytriol 
monoacetate (1.99) and 
cystoseirol monoacetate 
(1.100).29 All four 
compounds exhibited 
moderate cytotoxicity 
against the murine cancer 
cell line KA3IT, but reduced cytotoxicity against normal NIH3T3 cells.29  
 
An unidentified Cystoseira species (Canary 
Islands), yielded five meroditerpenes, amentol 
chromane diacetate (1.101), 14-
methoxyamentol chromane (1.102), 
cystoseirone diacetate (1.103), preamentol 
triacetate (1.104) and 14-epi-amentol triacetate (1.105).30  
O
O O
OAc
AcO O
(1.103)
O
OAc
OOAc
OAc
(1.104)
O
O
OAc
OAc
AcO
(1.105)  
 
O
H
H
OAc H
(1.97)
OH
H
H
OAc H
(1.98)
OH
H
H
OAc H OH
(1.99)
OH
H
H
OAc H OH
HO
(1.100)
O
O
O
R2O
R2O
(1.101) R1 = R2 = Ac
(1.102) R1 = H, R2 = Me
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(1.106)
O
O
OHHO H
H
HOOC
OH
OH
H
(1.109)
HOOC
O
OH
OR
H
(1.107) R = Me
(1.108) R = H
It can be suggested from the above compounds that Cystoseira myrica (Gulf of Suez) 
and the unidentified Cystoseira species (Canary Islands) can be classified as one of the 
more advanced species (phytochemically) of the Cystoseira genus based on the complexity 
of the terpenes produced. 
1.4.5 Stypopodium species 
The tropical brown alga Stypopodium zonale 
(origin unknown), yielded a stypolactone 
(1.106), a diterpenoid of mixed biogenesis that 
displayed weak cytotoxicity in vitro against the 
A-549 and H-116 cell lines.28 Another 
Stypopodium zonale sample, collected off the 
coast of Tenerife, was the source of three 
terpenoids (1.107) to (1.109).28 Structures and 
relative stereochemistries were determined from 
the methyl esters. The methyl ester of (1.109) 
exhibited in vitro cytotoxic activity against 
cancer cell lines.28  
 
Stypopodium flabelliforme 
(Long Island, Papua New 
Guinea), yielded five 
meroditerpenoids, 2β, 3α-
epitaondiol (1.110), 
flabellinol (1.111), 
O
OH
H
H
HO
H
(1.110)
OMe
HO
HO H
H H
(1.111)
O
O
HO H
H H
(1.112)
CHO
OHHO
O
H
HO
H
(1.113)
Chapter 1. Introduction 
 
____________________________________________________________________________________________________ 
23
flabellinone (1.112), stypotriolaldehyde (1.113) and stypohydroperoxide as well as the 
previously reported stypoldione.26  
1.4.6 Eisenia species 
The Eisenia genus is a common Pacific-coast Japanese species.30 Eisenia bicyclis, collected 
from Jogashima Island Japan, was the source of nine new oxyliplin compounds (1.114) to 
(1.122).29 
O
O
R
H
OH
H
(1.114) R = Cl
(1.115) R = Cl,     saturated
(1.116) R = I
(1.117) R = I,       saturated  
O
O
R
H
OH
H
(1.118)
   
O
O
O
(1.119)
 
H
H
Cl
O
HOOC
(1.120)            
H O
O
OH
HO
(1.121)       
O
O
O
(1.122)  
Another sample of Eisenia bicyclis, from Japan, yielded a new phloroglucinol derivative 
(1.123), and two known phloroglucinols.30  
Eisenia arborea from the Mugizaki coast in Japan, produced the anti-allergic 
phlorotannin phlorofucofucroeckol-B (1.124), an inhibitor of histamine release from rat 
basophile leukemia (RBL) cells.27  
As mentioned earlier, the presence of acetogenins and polyphenolics usually suggests a 
less advanced secondary metabolism and indicates that Eisenia is a relatively less complex 
genus compared to other genera in the brown alga family. 
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OH
OH
(1.130)
OH
HO O
OH
(1.131)
O
OH
OH
(1.132)
O
OH
OH
(1.133)
1.4.7 Bifurcaria species 
 
Four new acyclic diterpenes (1.125) to (1.128) were 
isolated from the brown alga Bifurcaria bifurcata, 
collected off the Atlantic coast of Morocco.31 
Another specimen of B. bifurcata, also from the 
Atlantic coast of Morocco, yielded two cytotoxic 
trihydroxylated diterpenes (1.129) and (1.130), based 
on 12-hydroxygeranylgeranil.30 
B. bifurcata (Southern Britany, France), yielded 
the linear diterpenoids (1.131)-(1.135).35  
It appears that variation between samples of 
Bifurcaria bifurcata from the same geographical 
location is similar to the variation between 
samples from very different geographical 
locations – all samples giving a range of closely 
related diterpenes. 
1.4.8 Spatoglossum species 
Two new aurones, 4-chloro-2-hydroxyaurone 
(1.136) and 4-chloroaurone (1.137) were isolated from 
Spatoglossum variabile, collected off Karachi, Pakistan. A 
synthesis of (all-Z)-henicosa-1,6,9,12,15,18-hexaene (1.138) 
starting from (all-Z)-icosa-5,8,11,14,17-pentaenoic acid 
(EPA) has been completed.31 Compound (1.136) was 
OH
OH
OH
(1.134)
OH OH
OH
(1.135)
O
Cl
OH
(1.136)
O
O
Cl(1.137)
OH
OH
OH
(1.129)
COR
OH
(1.125) R = OMe
(1.127) R = H
OH
(1.126)
(1.128)
OH CHO
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originally isolated from the brown alga Fucus vesiculosus.31 Another specimen of 
Spatoglossum variabile, collected from the coast off Karachi, produced two shikimate 
derivatives (1.139) and (1.140).28 
 
 
 
 
1.4.9 New Secondary Metabolites of Less Studied Species from 2003 to 2008  
The following genera were studied to a far lesser extent between the period 2003 to 2008 
and have shown structural classes reminiscent of genera described above and have also 
displayed significant biological activities. 
A dolabellane diterpene, hydroclathrol (1.141), was isolated from the brown alga 
Hydroclathrus tenuis.31 
Dilophus okamurae (Japan sea coast), yielded two diterpenoids 
sharing a novel carbon skeleton. Dictyterpenoids A (1.142) and B 
(1.143) displayed antifeedant activity against young abalone.28 
Undaria pinnatifida, obtained from Japanese waters, produced 
the secondary metabolites (1.144) to (1.146), where (1.144) is a 
unique loliolide derivative and (1.145) and (1.146) were 
determined to be diastereomers by nOe measurements.28 
OH
(1.141)
(1.138)
MeO
HO
OMe
COOR
(1.139) R = CH2CH2CH2CH3
(1.140) R = CH(CH3)2
(1.142)
H
H H
R
R = CHO
R = CH2OH(1.143)
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OAcO
OOH
OH
(1.144)  
OHO
OH
O
(1.145)  
OHO
OH
O
(1.146)  
Lobophora variegata, a common brown alga collected at several reef locations in the 
Bahamas and from the Red Sea, produced a 22-membered cyclic lactone lobophorolide  
(1.147).29 Lobophorolide (1.147) displayed potent and highly specific activity against the 
marine filamentous fungi Dendryphiella salina and Lindra thalassiae in addition to potent 
activity against C. albicans and antineoplastic activity against the HCT-116 cell line.29 
OMe
O O
O
O
O
OH
OMe
H
OMe
OH
H
OMeOMe
H
(1.147)  
Ecklonia stolonifera, collected from South Korea, yielded a new phlorotannin, 
eckstolonol (1.148), which possessed potent DPPH radical scavenging activity.29 
Scytosiphon lomentaria, cultured in deep seawater, produced the bisnorditerpene 
(1.149).30 
O
O O
O
OH
HO
OH
OHHO
(1.148)
O
HO
O
(1.149)
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Cystophora fibrosa (De Hoop Nature Reserve, South 
Africa), yielded a number of cyclised 
tetraprenyltoluquinols, of which (1.150)-(1.153) were 
new compounds.27 
O
O
OR2
OR3
R1O
(1.150) R1 = R2 = H, R3 = Me
(1.151) R1 = H, R2 = R3 = Me
(1.152) R1 = R3 = Me, R2 = H
(1.153) R1 = R2 = R3 = Me
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1.5 Overview 
In light of the above, a thorough investigation and research needs to be carried out to 
establish and understand the chemistry produced by each species of organism. There 
remains a gap in the literature whereby significant data about known compounds produced 
from certain species are often not reported.  
The synthesis of biologically active compounds is an important and integral part in the 
drug discovery process as is the understanding of the biosynthetic pathways and 
mechanism of action of the secondary metabolites. By understanding the biosynthesis, 
possible alternative methodologies to facilitate an adequate supply of the compound can be 
possibly realised. In doing so, initiation of the understanding of the secondary metabolites 
produced by these organisms needs to be understood, hence the purpose of 
chemotaxonomy. Drug discovery research in the area of marine natural products still 
remains a relatively new field in that many unexplored environments and organisms as 
simple as fungi36 are yet to be discovered. Nonetheless thousands of compounds with 
versatile and novel structural skeletons have been isolated from various marine 
organisms.32 In the quest for biologically active compounds, marine natural products have 
progressively entered clinical trials and have acted as the foundation of many synthetically 
produced bioactive compounds. However, much of the vast ocean still remains to be 
explored and understood.  
This thesis describes and evaluates several southern Australian marine brown algae with 
an emphasis placed on the phytochemical study of the Cystophora and Sargassum spp. The 
chemotaxonomic implications will also be discussed. 
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2. Phytochemical Profiling 
of Cystophora and 
Sargassum species 
2.1 Introduction 
The chemistry of various marine brown algae, belonging to the genera Sargassum and 
Cystophora were profiled in an effort to evaluate and compare their chemotaxonomic 
relationship. Secondary metabolites from these species can serve as valuable taxonomic 
markers.33 Phytochemical determinations may provide complementary information to 
morphological observations as a means for systematic classification.33 A comparative 
chemical study was motivated by the fact that biological testing (i.e. antitumour and 
antimicrobial activities) of the crude extracts of several Sargassum and Cystophora spp. in 
the MATNAP collection showed that the crude extracts of some species were more active 
than others. Evidence based on comparisons of the 1H NMR spectra and HPLC 
chromatographic analyses (including extracted UV profiles) of the crude extracts, 
supported the presence of an array of meroditerpenoids and linear diterpenoids. 
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2.2 Collection and Taxonomy 
In total there are ten separate specimens of Cystophora and Sargassum spp. in the 
MATNAP repository of samples, which were collected either by SCUBA or intertidally 
from Port Phillip Bay, Victoria, Australia. Each specimen was given a unique sample code 
and a voucher specimen is retained at the School of Applied Sciences, RMIT University. 
To date six of these brown algae have been investigated by the group including Sargassum 
sp. (2003-06), Sargassum fallax (2003-22), Sargassum decipiens (2003-23), Cystophora 
moniliformis (2004-09) and Cystophora retorta (2004-14) which have been studied and 
presented in this thesis. The sixth, Cystophora siliquosa (2003-08), was investigated by 
another member of the MATNAP research group. The remaining four specimens, which 
have not yet been investigated, include Cystophora retorta (2006-08), Cystophora torulosa 
(2006-10), Cystophora subfarcinata (2006-11) and Sargassum vestitum (2006-12).   
Brown algae of the genera Cystophora and Sargassum spp. belong to the families 
Cystoseiraceae and Sargassaceae respectively, and are well known to produce common 
secondary metabolites of the same structure class as the meroditerpenoids.33 Previous 
studies have shown that the structures of the meroditerpenoids isolated from the family 
Sargassaceae differ from those of the family Cystoseiraceae by having different 
substitution patterns of the hydroquinone moiety, cyclisations of side chains or the 
replacement of a methyl group by an oxygenated function.33 The purpose of this 
preliminary investigation was to survey the different types of compound classes produced 
by various Cystophora and Sargassum spp. in the MATNAP collection. This was carried 
out in order to aid in the selection of one of the Cystophora and one of the Sargassum 
specimens and subject these samples to a full chemical investigation. 
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2.3 Biological Screening 
The crude extracts (2 g of each specimen was extracted with 40 mL of 3:1 MeOH/DCM) 
of the ten algae in the collection displayed varying biological activities. As can be seen in 
Table 2.1, all samples either exhibited significant, moderate or weak antitumour activities 
(P388 assay, murine leukemia cell line), as well as moderate or no antimicrobial activity. 
On the basis of these activities, six of these samples were selected and chemically profiled. 
This analysis included the profiling of two Cystophora and three Sargassum spp. 
(highlighted in pale blue in Table 2.1). The sixth sample, highlighted in pale green in 
Table 2.1, was studied by another member of the MATNAP research group. 
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Table 2.1 Biological activities of the ten Cystophora and Sargassum spp. in the MATNAP collection (tested at 50 mg/mL).  
 
 
ND = No activity detected                * Zones of Inhibition (measured in mm) 
EC- Escherichia coli  CA- Candida albicans 
BS- Bacillus subtilis  TM- Trichophyton mentagrophytes 
PA- Pseudomonas aeruginosa CR- Cladosporium resinae 
Bioassay 
Sargassum 
sp. 
 
(2003-06) 
Cystophora
siliquosa 
 
(2003-08)
Sargassum
fallax 
 
(2003-22)
Sargassum 
decipiens 
 
(2003-23)
Cystophora 
moniliformis 
 
(2004-09)
Cystophora
retorta 
 
(2004-14)
Cystophora 
retorta 
 
(2006-08)
Cystophora 
retorta 
 
(2006-10)
Cystophora 
subfarcinata 
 
(2006-11)
Sargassum 
vestitum 
 
(2006-12)
Antitumour 
(ng/mL) 
P388 168,632 5,022 6,984 194,307 38,532 5,662 31,241 23,857 39,704 58,613 
EC ND 1 ND ND ND ND ND ND ND ND 
BS 2 3 2 ND ND 3 1 ND ND ND 
PA ND ND ND ND ND ND 3 ND 1 3 
CA ND 3 ND ND ND ND 3 ND 3 3 
TM ND 2 ND ND 4 4 1 ND ND 2 
Antimicrobial 
(mm)* 
CR ND 1 ND ND ND ND ND ND ND ND 
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2.4 Preliminary Investigation of Sargassum and Cystophora spp. 
The five specimens investigated were Sargassum sp. (2003-06), Sargassum fallax (2003-
22), Sargassum decipiens (2003-23), Cystophora moniliformis (2004-09) and Cystophora 
retorta (2004-14). The samples were extracted with 3:1 MeOH/DCM and subsequently 
sequentially partitioned (trituated) with DCM followed by MeOH. A preliminary analysis 
of the DCM and MeOH extracts was carried out by 1H NMR spectroscopy (Figure 2.3) 
and also by reversed phase HPLC. The HPLC analysis of the DCM partition (Figures 2.1 
& 2.2) of all extracts, indicated similar retention times between 28 to 32 minutes 
(corresponding to the elution with 100% CH3CN), indicative of a series of non-polar 
compounds. Variation between the two was observed between 14 to 27 minutes (elution 
with ~65% CH3CN/H2O), which suggested the presence of structural analogues of medium 
polarity. The presence of analogous compounds was confirmed by the similarity in the UV 
profiles displaying a UV maxima in the range of ~190 nm and ~330 nm. A combination of 
the HPLC retention times, 1H NMR spectra and UV profiles mentioned above suggested 
the presence of terpenoid and meroditerpenoid type compounds. The HPLC traces and 1H 
NMR spectra of the MeOH extracts were poorly resolved and thus did not invite any 
further speculation or analysis.  
Figures 2.1 and Figure 2.2 clearly show the existence of chemical diversity within the 
various Cystophora and Sargassum spp. examined. C. moniliformis (2004-09) and S. fallax 
(2003-22) displayed more complex HPLC chromatograms than the other species within the 
Cystophora and Sargassum genera, indicating a greater diversity in the range of secondary 
metabolites being produced. Terpenoid metabolites are useful chemotaxonomic markers 
because of their progressive structural complexity in advanced species and unique 
biogenetic origins.33 While numerous terpenoid variation studies have been described for 
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terrestrial plants, only a few investigations of terpenoid variation in marine plants have 
been documented.33,34 
 
 
 
 
Figure 2.1 HPLC analyses of DCM extracts of selected Cystophora spp. crude extracts 
from 0 to 32 minutes using a gradient elution from 10% to 100% CH3CN/H2O.  
Cystophora spp. 
UV= 254 nm 
2004-14 
2004-09 
UV= 210 nm 2004-09 
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Figure 2.2 HPLC analyses of DCM extracts of selected Sargassum spp. crude extracts 
from 0 to 32 minutes using a gradient elution from 10% to 100% CH3CN/H2O. 
 
1H NMR analysis of the DCM extracts of all five samples showed signals in the region 
6.0 – 7.0 ppm, which supported the presence of aromatic protons. Signals at ~5.0 ppm, 
were consistent with the presence of olefinic methines on a terpene chain. The 1H NMR 
spectrum for the Sargassum spp. displayed signals at ~3.0 ppm which is a methylene shift 
commonly found in plastoquinones.63,77 This information (1H NMR and HPLC) provided 
evidence of the common structure class known as the meroditerpenoids. The 1H NMR 
spectra of the Sargassum sp. specimens yielded the more complex HPLC traces and are 
shown in Figure 2.3. 
 
Sargassum spp. 
2003-22 
2003-06 
2003-23 
UV= 254 nm 
2003-22 UV= 210 nm 
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Sargassum sp. (2003-06) 
 
 
Sargassum fallax (2003-22) 
 
 
Figure 2.3 1H NMR spectra (300 MHz, CDCl3) of the DCM extracts of Sargassum sp. 
(2003-06) (Top spectrum) and Sargassum fallax (2003-22) (Bottom spectrum). 
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2.5 Conclusion 
The preliminary phytochemical survey of the crude extracts of six brown algae including 
Sargassum sp. (2003-06), Sargassum fallax (2003-22), Sargassum decipiens (2003-23), 
Cystophora moniliformis (2004-09) and Cystophora retorta (2004-14) assisted in selection 
of organisms for further study. Selection was based on the combination of the chemical 
inferences made on the basis of 1H NMR spectroscopy as well as the HPLC analyses, 
together with the biological activity as displayed by the crude extracts of the algae.  
The first sample chosen for further investigation was Cystophora moniliformis (2004-
09), which displayed a complex HPLC chromatogram (see Figure 2.1) with distinctive and 
resolved peaks. Although the 1H NMR spectrum of the DCM partition was not resolved 
and signals were not pronounced, magnification of the 1H NMR spectrum yielded signals 
of interest in the regions at ~ 3.0 ppm and ~5.0 ppm. Another sample of the same genus 
also chosen for investigation was Cystophora retorta (2004-14), which also yielded a 
complex and well-resolved HPLC trace. The 1H NMR spectrum of 2004-14 did not display 
many signals in the downfield region except around ~5.0 ppm. This was indicative of the 
presence of long chain fatty acids. The significant activity of the crude 2004-24 extract in 
the P388 antitumour assay was the fundamental reason for the selection of this species.   
For the purposes of comparison, three Sargassum species were chosen. Firstly, 
Sargassum fallax (2003-22) was chosen on the basis of its complex 1H NMR spectrum (see 
Figure 2.3), which directly showed the presence of aromaticity and structural diversity. 
The HPLC chromatogram was also well resolved (see Figure 2.2) and provided some 
evidence of structure classes as mentioned earlier. The second sample chosen was 
Sargassum sp. (2003-06), which displayed a comparatively interesting 1H NMR spectrum 
(see Figure 2.2 for evidence of aromaticity) and also a complex HPLC chromatogram (see 
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Figure 2.3). The final sample that was selected was Sargassum decipiens (2003-23), which 
was also very similar to Sargassum sp. (2003-06) in terms of HPLC retention times, 
complexity and the appearance of certain 1H NMR signals. Although Sargassum decipiens 
(2003-23) was chosen for investigation, lack of time prevented a thorough characterisation 
of this specimen. 
The phytochemical investigations of these specimens are described in Chapters 3 and 4. 
In particular, the complete chemical investigation of two of these algae, namely 
Cystophora moniliformis and Sargassum fallax (2003-06), ultimately resulted in the 
isolation of six new natural products.   
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3. Phytochemistry of 
Cystophora spp.1 
3.1 Chemotaxonomy of Cystophora species 
There are an estimated twenty three known Cystophora spp. for which the 
phytochemistry of approximately fourteen have been reported.37,33 As a result of suitable 
environmental conditions that have enabled its evolution, Cystophora spp. are endemic to 
the cool temperate waters of Australasia.32,33,38  
The two major genera of the Cystoseiraceae family include Cystoseira and Cystophora 
and on the basis of existing phytochemical data, the Cystoseira species were classified into 
three categories (A-C) based on the metabolites produced.39 Category A comprises those 
species that do not contain diterpenes, category B includes species that produce linear 
diterpenes and those in category C are species that contain meroditerpenoids.39 The 
meroditerpenes have been further subdivided into three classifications which include 
linear, cyclic and rearranged terpenoids.39 It was recognised that by identifying the degree 
of complexity in the terpenes produced by Cystoseira species, together with the 
morphological and reproductive data, that differences in the level of phylogenetic 
advancement could be ascertained.33,37,39,40 The assertion made was that, terpenes of 
greater complexity (e.g. cyclic and rearranged meroditerpenoids), are phylogenetically 
more advanced than others.39,40 The second major genus of the Cystoseiraceae family, 
Cystophora as well as other genera within the Cystoseiraceae family, are known to produce 
                                           
1The results of one of these studies has been published: Reddy, Priyanka; Urban, Sylvia. “Linear and Cyclic 
C18 Terpenoids from the Southern Australian Marine Brown Alga Cystophora moniliformis” Journal of 
Natural Products 2008, 71, 1441. 
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both isoprenoid and non-isoprenoid secondary metabolites with various functionalised 
carbon skeletons, making it frequently difficult to classify these genera to the species 
level.39 In many cases they are characterised by the presence of linear and cyclic C18 
terpenoid metabolites such as compounds (3.1) to (3.9) which can be regarded as specific 
markers of the Australian genera.39  
Generally, Cystophora spp. produce secondary metabolites such as phloroglucinols, 
halogenated phlorethols, polyenes, simple terpenes and rarely meroditerpenoids.40-55 The 
presence of terpenes as compared to acetogenins in brown algae has been suggested to be 
indicative of advanced secondary metabolism.33 In the case of Cystophora moniliformis, a 
range of fairly simple farnesyl acetone derivatives are known to be produced as well as 
simple meroditerpenoids.40 The sole species producing metabolites other than only 
acetogenins is C. moniliformis, which has yielded variously functionalised and cyclised 
farnesylacetone derivatives such as compounds (3.1) to (3.12) as well as related 
metabolites including the tricyclic terpene (3.13) and the lactone (3.14).33 Wells and co-
workers have reported the isolation of meroditerpenoids from Cystophora moniliformis 
including the chromanes, δ-tocotrienol (3.15) and α-tocopherol (3.16).50 
 
(3.1) (3.2)
(3.3) (3.4)
O
O
O
O
O
O
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This further supports the proposed phylogeny that has classified C. moniliformis as being 
one of the most developed species of this genus based on morphology alone, as indicated 
by Womersley (see Figure 3.1).33,37 Phycologists have often found it difficult to 
taxonomically identify brown algae to the species level.39 Additional information such as 
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phytochemistry is useful for this systematic taxononomic classification and it is here that 
chemotaxonomy can serve an important role.33,39  
Wells and co-workers have reported intriguing biological activity for the Cystophora 
spp.15 The lipophilic extracts of the Cystophora spp. displayed in vitro antimicrobial 
activity against gram-positive organisms and the compounds responsible for the activity 
were established to be phloroglucinol derivative (3.17), resorcinol derivative (3.18) and δ-
tocotrienol (3.15).50  
(3.17)
(3.18)
HO
OH
OH
HO OH
O
 
 
On the contrary, C. moniliformis had been reported to produce metabolites such as (3.1) 
to (3.14), for which the lipophilic extract showed no in vitro antimicrobial activity, but it 
did display weak anticonvulsant activity for which the major terpenoids, including the 
farnesyl acetone derivatives (3.3) and (3.4) were found to be responsible for this 
activity.50,56 According to Wells et al. these terpenoid ketones have also been suggested to 
have roles as feeding deterrents.47,53 The crude extracts of C. moniliformis were reported to 
display juvenile hormone activity and the isolated compounds, farnesyl acetone terpenoid 
(3.1) and its hexahydro-derivative (3.2) were analysed in the Galleria wax test (a test for 
hormonal activity) and were found to be not as active as the crude extract.47,53 
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Figure 3.1. The possible phylogenetic relationships of the species of Cystophora 
according to Womersley illustrating that Cystophora moniliformis belongs to one of the 
most advanced species of this genus.37 
Studied by the MATNAP research group
Reported in the literature 
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3.2 Cystophora moniliformis 
The marine brown alga Cystophora moniliformis was collected by SCUBA on the 30th 
April 2004 from Port Phillip Bay, Victoria, Australia. The alga was identified by Dr Gerald 
Kraft (Honorary Principal Fellow), Faculty of Science, School of Botany, University of 
Melbourne, Australia. A voucher specimen designated the code 2004-09 is deposited at the 
School of Applied Sciences, RMIT University. The phytochemical investigation of the 
brown alga C. moniliformis was stimulated on the basis of the moderate antitumour, 
antiviral and antifungal activities displayed by the crude extract of this specimen. This 
chapter describes the isolation and structure determination of two new cyclic farnesyl 
acetone terpenoids (3.25) and (3.26), a new linear terpenoid (3.27), a mixture of the known 
compounds (3.19) and (3.20), together with the first complete 2D NMR characterisation 
for the previously reported compounds (3.21) to (3.24). 
3.2.1 Extraction and Isolation 
The alga (20 g) was extracted with 3:1 CH3OH/DCM (700 mL) and the crude extract 
was decanted and concentrated under reduced pressure and subsequently sequentially 
partitioned by trituration into DCM, CH3OH and water-soluble extracts respectively. The 
DCM extract was fractionated using flash silica column chromatography (20% stepwise 
elution from n-hexane to DCM to EtOAc and finally to CH3OH). The 40:60 DCM/EtOAc 
silica column fraction was subjected to repeated gel permeation chromatography 
(Sephadex LH-20 using 100% CH3OH) followed by reversed phase HPLC (65% 
CH3CN/H2O) to yield compound (3.23) (12 mg, 0.14%), moniliforminol A (3.25) (6 mg, 
0.07%) and moniliforminol B (3.26) (6.5 mg, 0.08%).  
 
The 80:20 DCM/EtOAc silica column fraction was also subjected to gel permeation 
chromatography (Sephadex LH-20 using 100% CH3OH) and then reversed phase HPLC 
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(65% CH3CN/H2O) to yield a 3:1 mixture of compounds (3.19) and (3.20) (8 mg, 0.09%), 
compound (3.21) (5 mg, 0.06%), compound (2.22) (8 mg, 0.09%), compound (3.24) (7 mg, 
0.08%) and compound (3.27) (7 mg, 0.08%) (Scheme 3.1). 
 
3.2.2 Chromatography 
Fractions PR8 8.2 and PR8 10.2 (see Scheme 3.1) were initially subjected to an 
analytical HPLC analysis using a gradient method (0-2 mins 10% CH3CN/H2O; 14-24 
mins 75% CH3CN/H2O; 26-30 mins 100% CH3CN and 32-40 mins 10% CH3CN/H2O). 
After careful analysis and subsequent HPLC method development (as seen in Figures 3.2 
and 3.3) compounds (3.23), (3.25) and (3.26) were subsequently purified using a 60% 
isocratic method from fraction PR8 8.2 whilst a 65% isocratic HPLC method resulted in 
the isolation of compounds (3.19)-(3.22), (3.24) and (3.27) from fraction PR8 10.2.  
 
 
Figure 3.2. Semi-preparative HPLC chromatogram of fraction PR8 8.2 showing the 
elution and separation of moniliforminol A (3.25), B (3.26) and compound (3.23). The 
HPLC column used was a Phenomenex Prodigy C18 (250 x 10 mm) (5 µ), mobile phase 
60% CH3CN/H2O, flow rate of 3.5 mL/min with UV detection at 210 nm. 
 UV = 210 nm
Moniliforminol A (3.25) 
Moniliforminol B (3.26) 
Farnesyl acetone (3.23) 
1.2 2.5 3.8 5.0 6.2 7.5 8.8 10.0 11.2 
Chapter 3. Phytochemistry of Cystophora spp. 
 
____________________________________________________________________________________________________ 
46 
 
 
 
      
 
 
Figure 3.3. Semi-preparative HPLC chromatogram of fraction PR8 10.2 (see Scheme 
3.1). The HPLC column used was a Phenomenex Prodigy C18 (250 x 10 mm) (5 µ), mobile 
phase 65% CH3CN/H2O, flow rate of 3.5 mL/min, with UV detection at 210 nm. 
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)
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Scheme 3.1 Summary of isolation and purification method adopted for Cystophora 
moniliformis 
 
Moniliforminol A (3.25)
(6.0 mg) 
PR8 4.1    4.2…………4.7……….. 4.9…………..4.16
B
PR8  6.1…... 6.2 …………6.3 ............. 6.4
C
PR8  10.1…... 10.2 …………10.3 ……..10.4
A 
B 
       DCM 
PR8 3.1 (700 mL)
(0.25 g) 
Gravity filtration followed by evaporation 
PR8 3
(2.0 g) 
       MeOH 
PR8  7.1… 7.2 .…7.3… 7.4 
Moniliforminol B (3.26)
(6.5 mg) 
Compound (3.23)
(12 mg) 
Compound (3.27)
(7.0 mg) 
PR8  8.1…. 8.2 …8.3 … 8.4 
Compound (3.22)
(8.0 mg) 
Compound (3.21) 
(5.0 mg) 
B 
B 
Compound (3.24)
(7.0 mg) 
Cystophora moniliformis
2004-09 
3:1 MeOH:DCM (500 mL) 
PR8  3.2 (115 mL) 
(1.5 g) 
D 
Compound (3.19)-(3.20) 
(8.0 mg) 
A Flash silica chromatography (Particle size 0.063 – 0.200 μ) 20% stepwise elution (n-hexane, DCM, 
EtOAc and MeOH respectively) 
B Sephadex LH-20 size-exclusion chromatography (100% MeOH) 
C  Semi-preparative reversed phase HPLC (65% CH3CN/H2O) 
D  Semi-preparative reversed phase HPLC (60% CH3CN/H2O) 
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3.2.3 Structure Elucidation and Discussion of Previously Isolated Compounds 
3.2.3.1 Previously isolated compounds 
 
Compounds (3.19) and (3.20) were isolated as colourless viscous oils, and have been 
previously described..50 They were isolated in this study as a mixture in a ratio of 3:1 
respectively, and identified by comparison of the 1H NMR data to the literature data.50 As a 
result of their re-isolation, additional chemical shift assignments for (3.19) and (3.20) 
could be made (refer to Chapter 5: Experimental), including the full assignment of all 
methylene resonannces. Structural assignments were aided by the use of the Advanced 
Chemistry Development (ACD) proton and carbon prediction software.  
HO
O
HO
O
(3.19) (3.20)
1
4
8'
7'
1'3' 7
9
 
 
 
Terpenoids (3.21) to (3.24) have been previously reported but were identified solely on 
the basis of limited 1H and 13C NMR assignments and mass spectrometry.50,57 As a result 
of this study, structures (3.21) to (3.24) were confirmed and fully assigned by detailed 
spectroscopic analysis including the first complete unequivocal assignment of their 
structures by 2D NMR spectroscopy. The absolute configuration for the secondary alcohol 
in compound (3.21) was established by Horeau’s method. 50 Acid catalysed rearrangements 
of (3.19) gave a mixture of (3.19) to (3.21), thus establishing the absolute stereochemistry 
of all three compounds.50 
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Compound (3.23) was immediately identified as a known terpene possessing a 
characteristic combination of 1H NMR chemical shifts for example methines (δH 5.16 & 
5.07), methylenes (δH 2.47 & 2.27) and methyls (δH 1.60 & 1.16). This enabled the 
immediate recognition of the terpene chain of other compounds isolated from Cystophora 
moniliformis (see Figure 3.4). 
ppm (f1)
2.03.04.05.06.07.0
 
Figure 3.4. 1H NMR spectrum (500 MHz, CDCl3) of compound (3.23) and important 
HMBC and COSY correlations highlighted on the structure of compound (3.23). 
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3.2.4 Structure Elucidation and Discussion of Novel Compounds Isolated 
3.2.4.1 Moniliforminol A 
 
Moniliforminol A (3.25) was isolated as colourless oil for which high resolution ESIMS 
established the molecular formula as C18H32O3 (319.2252 [M+Na]+, calcd for C18H32O3Na, 
319.2249) possessing three degrees of unsaturation. The IR spectrum supported the 
presence of hydroxy groups (3401 cm-1), a ketone (1709 cm-1) and an olefinic moiety 
(1589 cm-1). Analysis of the NMR spectra (Table 3.1) revealed chemical shifts indicative 
of a methyl ketone (δH  2.13, δC 209.1 ppm), one olefinic methyl (δH 1.64, δC 16.3 ppm), 
three singlet methyls [(δH 0.79, δC 15.1 ppm), (δH 1.02, δC 28.3 ppm), (δH 1.15, δC 23.2 
ppm)], one olefinic double bond [(δH 5.08, δC 123.1 ppm) and (δC  137.4, s)] and a 
secondary alcohol methine (δH 3.32, δC 78.4).49 DEPT and HSQCAD NMR experiments 
supported the presence of five methyl, six methylene and three methine carbons while the 
remaining quaternary carbons were identified from the HMBC experiment (Table 3.1). 
Both COSY and HMBC correlations as well as comparison to the literature NMR data for 
compound (3.21), quickly established the presence of the linear terpene side-chain in the 
substructure of moniliforminol A (3.25).50 On the basis of the molecular formula, IR and 
NMR data, one degree of unsaturation still needed to be accounted for. A combination of 
HMBC and COSY correlations (Table 3.1) were able to establish the presence of a six 
membered ring unit, which accounted for the remaining degree of unsaturation. The 
selected COSY correlations shown in colour in Figure 3.6 correspond to the structure 
fragment A of moniliforminol A (3.25). Linking of the linear terpene moiety to the six 
membered ring was achieved through the observation of HMBC correlations from the 
methylenes at positions 7 and 8 to a methine at position 1’ on the six membered ring. In 
moniliforminol A (3.25) the C2’ and C5’ carbons were coincident at δC 41.1.  
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Figure 3.5. gHMBC experiment of moniliforminol A (3.25). The expansion indicates 
one of the diagnostic correlations (HMBC correlation from H1’ to C8) confirming the 
linkage of the linear terpene chain to the six membered ring. 
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Figure 3.6. Fragment A of moniliforminol A (3.25) showing selected COSY 
correlations that facilitated the assembly of the six membered ring unit. Full gCOSY NMR 
spectrum of moniliforminol A (3.25) and an expanded region of the gCOSY spectrum. The 
coloured lines represent selected correlations that correspond to fragment A of 
moniliforminol A (3.25) 
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Table 3.1. NMR Spectroscopic Data (500 MHz, CDCl3) for moniliforminol A (3.25) 
 
aCarbon assignments based on HSQCAD and DEPT experiments 
bOverlapped signals 
ND = Not Detected 
position δca, mult δΗ (J in Hz) gCOSY gHMBC Selective 1D nOe 
1 30.1, CH3 2.13, s 3 2  
2 209.1, qC     
3 43.9, CH2 2.48, t, (7.5) 1, 4 2, 4, 5  
4 22.6, CH2 2.26, m 3, 5   
5 123.1, CH 5.08, dt, (1.0, 7.0) 4, 9 3, 4, 7, 9  
6 137.4, qC     
7 42.9,  CH2 2.08, s 8a, 8b 8  
8a 24.3, CH2 1.55, m 7, 8b, 1’   
8b  1.42, m 7, 8a, 1’ 1’  
9 16.3, CH3 1.64, s 5 5, 6, 7  
1’ 55.4, CH 1.08, t,  (4.5) 8a, 8b 7, 8, 6’ 7, 3’, 5’b, 9’ 
2’ 41.1, qCb     
3’ 78.4, CH 3.32, dd, (4.0, 11.0) 4’a, 4’b  1’, 4’a , 5’b, 9’  
4’a 29.3, CH2 1.74, m 3’ 3’, 5’, 6’  
4’ b  1.50, m 5’a   
5’a 41.1,  CH2b 1.77, m 4’b 3’, 6’  
5’b  1.48, m    
6’ 73.5, qC     
7’ 23.2, CH3 1.15, s  1’, 5’, 6’ 8’ 
8’ 15.1, CH3 0.79, s 9’ 1’, 2’, 3’, 9’ 7’, 9’ 
9’ 28.3, CH3 1.02, s 8’ 1’, 2’, 3’, 8’ 7, 8b, 3’, 8’ 
3’-OH ND -    
6’-OH ND -    
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3.2.4.2 Moniliforminol B 
 
Moniliforminol B (3.26) was immediately recognised to be an epimer of moniliforminol 
A (3.25) on the basis of the similarity of the 1H and 13C NMR spectra (Table 3.2) between 
these two compounds. Moniliforminol B (3.26) was isolated as colourless oil and high 
resolution ESIMS confirmed that (3.26) had the same molecular formula as (3.25) 
C18H32O3 (319.2251 [M+Na]+, calcd for C18H32O3Na, 319.2249). The IR spectrum of 
(3.26) was very similar to (3.25) and again supported the presence of the hydroxy moieties 
(3369 cm-1), a ketone (1713 cm-1) and an olefinic double bond (1589 cm-1). Finally the UV 
spectra and extinction coefficients were almost identical for both moniliforminol A (3.25) 
and B (3.26). Stereochemical assignment of the double bonds of terpenoids (3.19) to (3.27) 
was made on the basis of the position of the vinyl methyl resonances in the 13C NMR 
spectrum (δC 15.9-16.4) for these compounds.58,59 Whilst the NMR data was very similar to 
(3.25), all of the carbon signals were resolved in (3.26) (Table 3.2) including the carbons 
at C2’ and C5’ C5’which were coincident in the 1H NMR spectrum of (3.25). The 
deshielded resonance attributed to C7’ in (3.26) (δC 30.7 ppm) relative to (3.25) (δC 23.2 
ppm) was interpreted as having a cis disposition with respect to the proton at position 1’ in 
(3.26) whilst a trans disposition was concluded between C7’ and the proton at position 1’ 
in (3.25).60 This conclusion is based on energy minimised structures of (3.25) and (3.26) 
which indicate additional interactions in (3.25) and provided further support for the 
epimeric disposition at position 6’. 
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Figure 3.7. 1H NMR spectrum (500 MHz, CDCl3) of moniliforminol B (3.26). 
 
 
Figure 3.8. High Resolution ESI (positive mode) mass spectrum of moniliforminol B 
(3.26).  
 
The relative configuration of moniliforminol A (3.25) and moniliforminol B (3.26) was 
determined by single irradiation nOe NMR experiments with selective irradiations shown 
in Figure 3.9. These key nOe enhancements confirmed that moniliforminol A (3.25) and 
p p m  ( f1 )
1 .02 .03 .04 .05 .06 .07 .08 .0
OHO
OH
(3.26)
[M+Na]+ 
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moniliforminol B (3.26) were epimeric with a reversed orientation of the hydroxy and 
methyl substituents at position 6’. 
3.2.4.3 Absolute stereochemistry of the epimers 
The 1H NMR coupling constants of the hydroxy methine proton support the 
stereochemical assignment as equatorial in both (3.25) and (3.26). After examination of the 
available literature26-31 describing Cotton Effects displayed by similar terpenoids, we were 
able to assign the absolute configuration to (26) on the basis of a positive Cotton effect 
(Δε230 nm +6.67) in the CD spectrum of this compound, which was compared with that 
observed for (28) (Δε239.5 nm +11.01).61 The absolute configuration of the secondary alcohol 
in (3.28) had been previously established by application of the Mosher method, which 
subsequently allowed the complete absolute configuration of (3.28) to be assigned.26  
O
HO
(3.28)
1'
 
The absolute configuration of (3.28) was further corroborated by recording its CD 
spectrum.26 The positive Cotton effect at 239.5 nm in the CD spectrum of (3.28) allowed 
the absolute configuration at position 1’ to be assigned on the basis of the octant rule.26 As 
such, a positive Cotton effect at 230 nm in the CD spectrum of (3.26) supported the 
absolute configuration about position 1’ in (3.26) as being the same as that reported in 
(3.28). In defining the absolute configuration about position 1’ in (3.26), it followed that 
the complete absolute configuration of this compound could be ascertained on the basis of 
the relative disposition of remaining centers to position 1’, as established previously by 
nOe NMR experiments. Since (3.25) was confirmed to be the position 6’ epimer of (3.26), 
the absolute configuration of (3.25) could also be tentatively assigned by inference to the 
absolute configuration established for (3.26).  
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Figure 3.9. Selective 1D nOe NMR experiments confirmed that moniliforminol A 
(3.25) and moniliforminol B (3.26), have opposite configurations at position 6’. 
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Table 3.2. NMR Spectroscopic Data (500 MHz, CDCl3) for moniliforminol B (3.26) 
position δca, mult δΗ (J in Hz) gCOSY gHMBC Selective 1D 
nOe 
1 30.2, CH3 2.14, s  2, 3  
2 209.0, qC     
3 43.9, CH2 2.48, t, (7.0) 4, 5 2, 4, 5  
4 22.6, CH2 2.26, q, (7.5) 3, 5 2, 3, 5, 6  
5 122.8, CH 5.11, dt, (1.5, 7.5) 3, 4, 9 4, 7, 9  
6 137.0, qC     
7 43.6, CH2 2.03, m 8a, 8b, 9   
8a 24.8, CH2 1.51, m 7 6’  
8b  1.44, m 7   
9 16.4, CH3 1.66, s 5 5, 6, 7  
1’ 53.2, CH 0.83, dd,  (2.5, 4.5)   3’, 4’b, 7’, 9’  
2’ 40.5, qC     
3’ 78.8, CH 3.25, dd, (4.5, 12.0) 4’a, 5’ b 8’, 9’ 1’, 4’a, 9’  
4’a 27.2, CH2 1.80, m 3’, 4’b  3’, 4’b, 8’  
4’ b  1.62, m 4’a   
5’a 39.2, CH2 1.68, m 5’b  5’b 
5’b  1.52, m 3’, 5’a, 7’   
6’ 72.7, qC     
7’ 30.7, CH3 1.17, s 5’b 1’, 5’, 6’ 1’, 5’b, 9’ 
8’ 14.9, CH3 0.93, s 9’  1’, 2’, 3’, 9’ 4’a 
9’ 27.1, CH3 0.97, s 8’ 1’, 2’, 3’, 8’ 1’, 3’ 
3’-OH ND -    
6’-OH ND -    
 
aCarbon assignments based on HSQCAD and DEPT experiments 
ND = Not Detected 
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3.2.4.4 Isolation and Identification of Compound (3.27) 
Compound (3.27) was also isolated as colourless oil and high resolution ESIMS 
established the molecular formula as C19H34O3 (333.2401 [M+Na]+; calcd for C19H34O3Na, 
333.2406). The NMR data (Table 3.3) were very similar to the previously isolated 
compound (3.23) indicating that (3.27) had the same linear terpene carbon skeleton.50 The 
only significant difference was a singlet at δH 3.22 correlating to a carbon at δC 49.7 ppm 
in the HSQCAD and δC 77.6 ppm in the HMBC experiment, together identified the 
presence of a methoxy moiety in (3.27). Also, HMBC correlations confirmed the position 
of the methoxy moiety in the structure of (3.27). Compound (3.27) was confirmed to be the 
methylated analogue of compound (3.23). The absolute configuration of the secondary 
alcohol in (3.23) had been previously established by recording the CD of the hydrolysis 
product of (2.4) using the method of Nakanishi.12,15 The coupling constant of the hydroxy 
methine in (3.23) (δH 3.36 dd J=1.5, 10.5 Hz) was the same as in (3.27) (δH 3.42 dd J=1.5, 
10.5 Hz) and as such, the secondary alcohol in both (3.23) and (3.27) were assigned the 
same configuration.  
3.2.4.4.1 Origin of the new linear chain  
It was thought possible that (3.27) may have arisen as an artifact of the isolation 
procedure, derived originally from compound (3.23) in an acid-catalysed transformation 
brought by from exposure to MeOH during the extraction procedure. In an effort to test 
this hypothesis a sample of (3.23) was left in MeOH over a week, another was placed in 
MeOH and heated and the third was placed in MeOH with three drops of formic acid and 
left for a week. Samples were then evaporated to dryness and re-suspended in CHCl3 and 
analysed via GC-MS. Retention times of compounds (3.23) and (3.27) in CHCl3 were used 
to monitor the possible formation of compound (3.27) from (3.23). In the three varying 
experiments undertaken no evidence of (3.27) was apparent in any of the GC-MS analyses 
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and so it cannot be definitively concluded if (3.27) is an artifact or an actual natural 
product. Due to the similarity of the coupling constant for the hydroxy methine in (3.27) 
and (3.23) as well as their co-occurrence, on biosynthetic grounds, the same absolute 
configuration has been assigned for compound (3.27) about the secondary alcohol.  
O
H3CO
OH
1
3613
17
15
(3.27)    
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Table 3.3. NMR Spectroscopic Data (500 MHz, CDCl3) for compound (3.27) 
position δca, mult δΗ (J in Hz) gCOSY gHMBC 
1 30.4, CH3 2.13, s  2, 3 
2 209.1, qC    
3 43.8, CH2 2.46, t, (7.5) 4 1, 2, 4, 5 
4 22.8, CH2 2.26, m 3, 5 2, 3, 5, 6  
5 122.7, CH 5.07, t, (6.5) 4 3, 4, 7, 18 
6 136.6, qC    
7 39.8, CH2 1.98, m 8 5, 6, 8, 18 
8 26.8, CH2 2.07, m 7, 9 7, 9, 10 
9 124.7, CH 5.14, t, (6.5) 8 7, 8, 11, 17 
10 135.4, qC    
11a 37.0, CH2 2.27, m 11b, 12a 10 12, 13 
11b  2.03, m 11a 12, 13, 17 
12a 29.9, CH2 1.50, m 11a, 12b 11 
12b  1.39, m 12a, 13 11 
13 76.6, CH 3.42, dd, (1.5, 10.5) 12b 11, 12, 14, 16 
14 77.6, qC    
15 21.2, CH3 1.12, s  13, 14, 16 
16 19.0, CH3 1.10, s  13, 14, 15 
17 16.3, CH3 b1.61, s   9, 10, 11a 
18 16.3, CH3 b1.61, s  5, 6, 7 
19 49.3, CH3 3.22, s  14 
13-OH ND    
 
aCarbon assignments based on HSQCAD and DEPT experiments 
bOverlapped signals 
ND = Not Detected 
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3.2.5 Biosynthesis 
It is proposed that moniliforminol A (3.25) and moniliforminol B (3.26) could be 
biosynthetically produced from acid catalysed cyclisation of compound (3.23) which, like 
all terpenes, is derived from geranyl pyrophosphate (see Figure 3.4). However, the 
absolute configuration of the chiral centre of compound (3.23) does not match the 
proposed derivatives moniliforminol A (3.25) and B (3.26).  A possible explanation could 
be either enzymatic inversion or that the enantiomer of compound (3.23) was never 
isolated due to its consumption in this reaction. Also, it is possible that compounds (3.19) 
to (3.21) are also cyclised terpenes, which are derivatives of moniliforminol A (3.25) and 
moniliforminol B (3.26) formed via dehydration reactions. The isolation of the more 
complex terpenoids (3.25) and (3.26) lends further support for C. moniliformis being one 
of the most developed species of the genera and are potential chemotaxonomic markers for 
this species (see Figure 3.1).   
O
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Figure 3.10. Proposed biosynthetic pathway for the formation of moniliforminol A 
(3.25) and B (3.26). 
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It is proposed that the precursor of compounds (3.24), (3.22), (3.25), (3.26) and (3.27) is 
compound (3.23). A simple methylation, dehydration or dehydration accompanied by 
simple rearrangement of (3.23) leads to the formation of (3.27), (3.22) and (3.24) 
respectively. Figure 3.12 demonstrates the formation of moniliforminol A (3.25) and 
moniliforminol B (3.26) which are the proposed precursors of (3.19), (3.20) and (3.21). 
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Figure 3.11. Proposed biosynthetic pathway of the compounds isolated from Cystophora 
moniliformis  
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3.2.6 Conclusion & Biological Activity 
The crude extract of Cystophora moniliformis displayed moderate antitumour activity 
(IC50 of 38532 ng/mL at 50 mg/mL). In addition the extract displayed cytotoxic activity 
against the H. simplex and the Polio virus as well as moderate antimicrobial activity (a 4 
mm zone of inhibition was detected against Trichophyton mentagrophytes). No activity 
was observed for the extract against Eschericha coli, Pseudomonas aeruginosa, Candida 
albicans, Bacillus subtilis, or Cladosporium resinae. 
Compounds (3.21) to (3.27) displayed no appreciable antitumour activity (IC50 of >40 
μM when tested at 1 mg/mL) or antifungal activity (1 mm zone of inhibition detected 
against Trichophyton mentagrophytes). The mixture of compounds (3.19) and (3.20), 
obtained in a 3:1 ratio, displayed moderate antitumour activity (IC50 of 45 μM when tested 
at 1 mg/mL) and moderate antifungal activity (4 mm zone of inhibition detected against 
Trichophyton mentagrophytes). All other isolated compounds showed no inhibition of 
Trichophyton mentagrophytes when tested at 1 mg/mL. Recently the antiviral assays 
conducted at the University of Canterbury were phased out which meant that no antiviral 
assessment of the isolated compounds could be carried out. 
The linear terpene (3.24) and related polyprenyl ketones have been previously described 
as synthetically prepared derivatives that have been patented for their antiulcer activity and 
hypotensive activity.22 This represents the first report of compound (3.24) occurring as a 
natural product. 
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3.3 Cystophora retorta 
The brown alga, Cystophora retorta was collected on the 30th April, 2004 from Port 
Phillip Bay, Victoria, Australia. The alga was identified by Dr Gerald Kraft (Honorary 
Principal Fellow), School of Botany, University of Melbourne, Australia. A voucher 
specimen designated the code 2004-14 is deposited at the School of Applied Sciences, 
RMIT University. The chemical profiling of the brown alga C. moniliformis was 
stimulated on the basis of the potent antitumour activity (IC50 of 5662 ng/mL @ 50 
mg/mL) as well as moderate antiviral and antifungal activities displayed by the crude 
extract of the specimen. In the process of trying to establish the nature of the compound(s) 
responsible for the observed crude extract activity, δ-tocotrienol (3.15) was isolated and 
the evidence of other related structural analogues could be presented on the basis of HPLC 
analyses.  
 
3.3.1 Extraction and Isolation 
A total wet weight of 82.3 g of the brown alga, Cystophora retorta, was extracted with 
700 mL of 3:1 MeOH/DCM. The crude extract was filtered and evaporated to produce a 
mass of 4.66 g and then subjected to fractionation according to Scheme 3.2. Following 
extraction the crude extract was decanted and concentrated under reduced pressure and 
subsequently sequentially solvent partitioned by trituration into DCM, MeOH and water-
soluble extracts respectively. The DCM extract was fractionated by flash silica column 
chromatography (20% stepwise elution from n-hexane to DCM to EtOAc and finally to 
CH3OH). The 80:20 DCM/EtOAc silica column fraction yielded δ-tocotrienol (3.15) (70 
mg). This compound was not responsible for the potent antitumour activity observed in the 
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crude extract. In pursuit of the compound(s) responsible for this activity, further 
fractionation of the extract was carried out (Scheme 3.2). 
3.3.1.1 Chromatography 
Fraction PR1 10.7 (Scheme 3.2) was analysed by reversed phase analytical HPLC by 
monitoring at 254 nm (see Figure 3.12). The compound δ-tocotrienol (3.15) has a UV 
maximum at ~290 nm with possible structural analogues having a similar UV profile as 
shown in Figure 3.12 were also detected. The UV profiles were extracted from the HPLC 
2D contour plot of the fraction PR1 10.7  
 
Figure 3.12. Reversed phase HPLC chromatogram of fraction PR1 10.7 and 
corresponding UV profiles of structural analogues  
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Scheme 3.2 Summary of isolation and purification method adopted for Cystophora 
retorta  
PR1 30.1…… 30.9………  30.11
Gravity filtration followed by evaporation 
PR1  31.1……31.8…31.12 
C
PR1 32 
(0.5 mg) 
D
D 
PR1 3.2 (115 mL) 
(4.36 g) 
PR1 3.1 (700 mL) 
(0.25 g)
A 
E 
 
A Flash silica chromatography (Particle size 0.063 – 0.200) 20% stepwise elution (using n-Hexane, DCM, 
EtOAc and MeOH respectively) 
B C18 Vacuum Liquid Chromatography (VLC) 20% stepwise elution (using Water, MeOH, DCM)  
C Sephadex LH-20 using 100% MeOH 
D Diol cartridge using a 20% n-Hexane/DCM to 100%DCM to 50%DCM/MeOH to 100% MeOH 
        DCM 
B
PR1    6.1……6.10 ………..6.11……   6.21PR1 10.1…δ-tocotrienol (70 mg)…...10.16 
Combined  
Cystophora retorta
2004-14 
3:1 MeOH:DCM (700 mL) 
C
PR1 3
(4.66 g) 
       MeOH 
PR1    13.1……….13.7……………  13.8
PR1  22  
PR1   22.1………………..22.6 
(0.2 to 0.5 mg) 
PR1   21.1…………..21.6
E
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3.3.2 Structure Elucidation and Discussion 
 δ-tocotrienol (3.15) had been previously reported and identified on the basis of 1H and 
13C NMR assignments and mass spectrometry.50 The 1H NMR spectrum of δ-tocotrienol 
(3.15) (see Figure 3.12) displayed signals at δΗ 6.49 & δΗ 6.51 representing two m-
coupled doublets (J=2.6 Hz) corresponding to H2’ and H4’ respectively. The methyl group 
(C8b) attached to the aromatic ring occurs as a singlet at δΗ 2.18. Other signals in the 1H 
NMR spectrum, including the olefinic methyls (δΗ 1.60 & δΗ 1.72) and the olefinic 
methines (δΗ 5.14, 3H, H-3’, H-7’ and H-11’), supported the assignment of the terpene 
moiety.  
 
Figure 3.13. 1H NMR spectrum (300 MHz, CDCl3) of δ-tocotrienol (3.15).  
The structure of δ-tocotrienol (3.15) was confirmed on the basis of a full 1D and 2D 
NMR analysis. Selected HMBC correlations for δ-tocotrienol (3.15) are shown in Figure 
3.14.  
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Figure 3.14. Selected HMBC correlations of δ-tocotrienol (3.15) 
The GC-MS of fraction PR1 10.7 (Figure 3.15) showed the presence of a molecular ion 
(m/z 396) [M]+ for δ-tocotrienol (3.15) as well fragments ions arising from loss of the side 
chain [M-219]+ and cleavage of the chromanol ring [M-259]+.  
 
Figure 3.15.  GC-MS spectrum of δ-tocotrienol (3.15) and the proposed fragmentation 
that occurred to explain the major ion peaks M+ -259 and M+ -219.  
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3.3.3  Conclusion & Biological Activity 
Based on the potent antitumour activity displayed by the crude extract of C. retorta an 
attempt to pursue the compound(s) responsible for this activity was made. However, 
chemical investigation of the extract resulted in the isolation of δ-tocotrienol (3.15), which 
was found to only display weak antitumour activity (IC50 of 159 μM).  It is important to 
acknowledge that there are minor impurities present in δ-tocotrienol (3.15), evident in the 
upfield region of the 1H NMR spectrum.  It is possible that these impurities may have 
affected the resulting antitumour activity. Since the compound(s) responsible for the 
observed activity in the crude extract have yet to be established, further work was carried 
out on selected column fractions (See Scheme 3.2). The masses obtained for these semi-
purified fractions were too minuscule to attempt any further purification and 
characterisation. In order to pursue the bioactive constituents, it is likely that a recollection 
of the organism will be needed in order to have sufficient extract to purify. This will 
hopefully lead to sufficient quantities of purified bioactive compound(s) to permit 
subsequent characterisation. 
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4. Meroditerpenoids from 
Sargassum species1 
4.1 Phytochemistry of Sargassum species 
The phytochemistry of an estimated 62 species of the Sargassum genus (Sargassaceae, 
Fucales) has been reported to date.36 Sargassum species are found throughout tropical and 
subtropical areas of the world and are reported to produce secondary metabolites of 
structural classes such as plastoquinones,67-69 chromanols,70 chromenes,71,72 steroids73 and 
glycerides.74 The meroditerpenoids (plastoquinones, chromanols and chromenes), 
consisting of a polyprenyl chain attached to a hydroquinone ring moiety, are present in 
many marine organisms such as coelenterates, fish, macroalgae, sponges and tunicates.71  
Brown algae (division Phaeophyta) produce a myriad of secondary metabolites of this 
class, making members such as sargaquinone (4.1), sargaquinoic acid (4.2) and 
sargahydroquinoic acid (4.3) representative of just a few of the meroditerpenoids produced 
by these organisms. 71 
(4.1)
O
O
 
O
O
COOH
(4.2)  
                                           
1The results of one of these studies has been published:: Reddy P., Urban S. “Meroditerpenoids from the 
Southern Australian Brown Alga Sargassum fallax” Phytochemistry, 2009, 70, 250.  
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Plastoquinones from the Sargassum genus generally adopt the same structural skeleton 
and differ primarily in the linear terpene chain moiety.36  
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4.2 Sargassum fallax 
The marine brown alga Sargassum fallax was collected by SCUBA on the 11th 
September 2003 from Port Phillip Bay, Victoria, Australia. The alga was identified by Dr 
Gerald Kraft, School of Botany, University of Melbourne, Australia. A voucher specimen 
designated the code 2003-22 is deposited at the School of Applied Sciences, RMIT 
University. Moderate antitumour activity was observed for the crude extract (3:1 
MeOH/DCM) of the alga (IC50 of 6,984 ng/mL when tested at 50 mg/mL). In addition,. the 
extract displayed cytotoxic activity against the Herpes simplex virus and the Polio virus as 
well as moderate antimicrobial activity with a zone of inhibition detected against Bacillus 
subtilis. An attempt to isolate the compounds responsible for the biological activity 
displayed in the crude extract was made. Also a comparative study of the Sargassum spp. 
within the MATNAP collection was conducted in an attempt to conduct a rapid 
phytochemical analysis between species. This chapter describes the isolation and structure 
determination of three new meroditerpenoids, fallahydroquinone (4.8), fallaquinone (4.9) 
and fallachromenoic acid (4.10). The identification of the known meroditerpenoids 
sargaquinone (4.1) (isolated as a mixture with sargaquinoic acid (4.2)), sargahydroquinoic 
acid (4.3) and sargachromenol (4.11) is also described. The complete 2D NMR 
characterisation for (4.2) and (4.3) are reported for the first time and additional 
spectroscopic characterisation data have been reported for (4.11). 
4.2.1  Extraction and Isolation 
The alga (2003-22, 36.3 g) was extracted with 3:1 MeOH/DCM (500 mL). The crude 
extract was then decanted and concentrated under reduced pressure and subsequently 
sequentially solvent partitioned by trituration into DCM, MeOH and water. The DCM 
extract was subjected to a flash silica column (20% stepwise elution from petroleum spirits 
to DCM to EtOAc and finally to MeOH). The 100% EtOAc silica column fraction was 
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subjected to gel permeation chromatography (Sephadex LH-20 using 100% MeOH) 
followed by reversed phase HPLC (80% CH3CN/H2O) resulting in the isolation of 
fallahydroquinone (4.8) (10 mg, 0.13%). The 40:60 DCM/EtOAc silica column fraction 
was subjected to gel permeation chromatography (Sephadex LH-20 using 100% MeOH) 
followed by reversed phase HPLC (85% CH3CN/H2O) to yield sargaquinoic acid (4.2) (8 
mg, 0.1%), sargahydroquinoic acid (4.3) (8 mg, 0.1%), fallaquinone (4.9) (5.0 mg, 0.06%) 
and sargachromenol (4.11) (10 mg, 0.13%). The remaining DCM extract was separately 
purified by reversed phase HPLC to yield predominately sargaquinone (4.1) (in a mixture 
with sargaquinoic acid (4.2)) (5 mg, 0.06%) and predominately fallachromenoic acid 
(4.10) in a mixture with sargachromenol (4.11)) (5 mg, 0.06%) (Scheme 4.1).  
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4.2.1.1 Chromatography 
The Sephadex LH-20 fraction designated as PR7 6.4 (see Scheme 4.1 for details) was 
initially subjected to analytical HPLC using a gradient method (0-2 mins 10% 
CH3CN/H2O; 14-24 mins 75% CH3CN/H2O; 26-30 mins 100% CH3CN and 32-40 mins 
10% CH3CN/H2O). After careful analysis and HPLC method development, an isocratic 
HPLC separation method was developed (85% CH3CN/H2O) as shown in Figure 4.1, 
which was subsequently used to purify fallahydroquinone (4.8). 
 
 
 
Figure 4.1. Semi-preparative HPLC chromatogram illustrating the separation of 
fraction PR7 6.4 (see Scheme 4.1) which resulted in the purification of fallahydroquinone 
(4.8). A Phenomenex Prodigy C18 250 x 10 mm (5 μ) column, mobile phase of 85% 
CH3CN/H2O, flow rate of 3.5 mL/min column and UV detection at 254 nm were adopted 
for this purification. 
 
 
 
 
PR7 6.3 Fallahydroquinone (4.8) PR7 6.5 
Fallahydroquinone 
(4.8), UV maxima at 
290 nm 
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Scheme 4.1 Summary of isolation and purification method adopted for Sargassum fallax  
 
PR7 4.1 …. 4.2… .…4.9……............4.11……….…….4.16 
PR7 7.1…..7.2 ……7.3 ....... 7.4……7.5
C
PR7  6.1 …6.4 …..6.7 
A 
B
       DCM 
PR7 3.1 (700 mL)
(0.25 g) 
Gravity filtration followed by evaporation 
PR7 3
(0.8 g) 
       MeOH 
Fallahydroquinone (4.8)
(10 mg) 
B 
Sargahydroquinoic (4.3)
(8 mg) 
PR7 7.1…... 7.2 ….... 7.5
C
Sargachromenol (4.11)
(10 mg) 
C 
Sargaquinone (4.1) 
(5 mg) 
PR7 3.2 (115 mL) 
(0.5 g) 
Fallaquinone (4.9) 
(5 mg) 
Sargaquinoic acid (4.2)
(8 mg) 
Fallachromenoic acid (4.10)
(5 mg) 
Sargassum fallax
2003-22 
3:1 MeOH:DCM (500 mL) 
A Flash Silica Column (Particle size 0.063 – 0.200 μ) 20% stepwise elution (using n-hexane, DCM, 
EtOAc and MeOH respectively) 
B Sephadex LH-20 column (100% MeOH) 
C Semi-preparative reversed phase HPLC (85% CH3CN/H2O) 
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4.2.2 Structure Elucidation and Discussion of Compounds Isolated 
Sargaquinone (4.1) was isolated in a mixture with sargaquinoic acid (4.2) in a ratio of 
1:20 as ascertained from the proton NMR integration and was identified on the basis of a 
direct comparison of its 1H and 13C NMR data with that reported in  the literature.75  
Sargahydroquinoic acid (4.2) was also isolated without any (4.1) contamination and 
sargaquinoic acid (4.3) was isolated with minor impurities. The acid (4.2) had been 
previously reported but was identified solely on the basis of 1H NMR assignments and 
mass spectrometry. The other isolated acid, sargaquinoic acid (4.3), had been previously 
been identified based on a combination of 1H and 13C NMR assignments and mass 
spectrometry.67,76-78 The re-isolation of (4.2) and (4.3) in this study provided the 
opportunity to report the first 13C NMR data for sargahydroquinoic acid (4.2) as well as 
complete unequivocal structural assignment of both compounds using 2D NMR 
spectroscopy. 
The 1H NMR spectrum shown in Figure 4.2 is that of sargahydroquinoic acid (4.2). The 
signals at δΗ 6.48 & δ 6.51 represent two m-coupled doublets (J=2.6 Hz) corresponding to 
H3 and H5 respectively, while the methyl group (C7) attached to the quinone moiety 
appears as a singlet at δΗ 2.17. Other signals in the 1H NMR spectrum, specifically the 
olefinic methyls (δΗ 1.74 & 1.58) and the olefinic methines (δΗ 5.09 & 5.95), supported the 
assignment of the terpene side chain moiety.  
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Figure 4.2. 1H NMR spectrum (500 MHz, CDCl3) of sargahydroquinoic acid (4.2). The 
downfield shift of the methylene doublet at H1’ (δH 3.28) is a diagnostic chemical shift 
indicating the presence of a hydroquinone moiety of the meroditerpenoid. 
 
The full assignment of sargahydroquinoic acid (4.2) was achieved via detailed 
spectroscopic techniques including 1D and 2D NMR (see Chapter 5: Experimental). On 
the basis of the correlations observed in the COSY and HMBC 2D NMR experiments, the 
methylene and methines could be unambiguously assigned. This, together with the HSQC 
correlations allowed complete assignment of both proton and carbon signals for (4.2) and 
(4.3). Selected COSY and HMBC correlations are shown in Figure 4.3. 
 
 
 
 
 
Figure 4.3. Selected HMBC and COSY correlations that facilitated the structural 
assignment of sargahydroquinoic acid (4.2). 
  
OH
OH
COOH
4' 8'
5' 9' 13'
5
1'
HMBC 
COSY 
(4.2) 
Methylene doublet 
H1’ δH 3.28 ppm 
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4.2.2.1 Fallahydroquinone 
The novel compound Fallahydroquinone (4.8) was isolated as a pale yellow oil, for 
which high resolution ESIMS established the molecular formula as C27H40O4 (451.2812 
[M+Na]+, calcd for C27H40O4Na, 451.2824), possessing eight degrees of unsaturation.  
(4.8)
HO
OH
CH2OH
OH 14'
3
2
1'
3'
5'
7'
9'
18' 16'
7
 
The IR spectrum supported the presence of hydroxy (3369 cm−1) and olefinic moieties 
(1441 cm−1). It also displayed a carbonyl stretch (w 1653 cm−1), indicative of a conversion 
of (4.8) to its oxidised analogue fallaquinone (4.9), which is typical behaviour for 
hydroquinones upon exposure to air.68 Analysis of the 1H NMR spectrum of (4.8) (Table 
1) revealed chemical signals typical of a meroditerpenoid with diagnostic 1H and 13C NMR 
shifts of a terpene chain, when compared to the known compound sargahydroquinoic acid 
(4.2). The 1H NMR spectrum showed the presence of an AB system (δH 6.51 and 6.48, J = 
3.0 Hz), which was assigned to two meta-coupled aromatic protons with associated 13C 
NMR chemical shifts of 114.1 and 115.6 ppm respectively (HSQC data). The characteristic 
chemical shift for the methylene doublet (δH  3.28, δC 29.8) immediately suggested a 
hydroquinone to terpene chain linkage. This was supported by the 1H NMR spectrum of 
sargahydroquinoic acid (4.2) and sargaquinoic acid (4.3) where the downfield methylene 
doublet H1’ (δH 3.28) immediately confirmed the presence of the hydroquinone moiety in 
sargahydroquinoic acid as shown in Figure 4.2. Conversely, the upfield methylene doublet 
at H1’ (δH 3.12) suggested a quinone moiety (see Figure 4.4) corresponding to 
sargaquinoic acid and immediately distinguished the two compounds. 
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Figure 4.4. 1H NMR spectrum (500 MHz, CDCl3) of sargaquinoic acid (4.3). The 
upfield methylene doublet at H1’ (δH 3.12) immediately suggested the presence of the 
quinone moiety of the meroditerpenoid. 
 
The 1H NMR spectrum also revealed vicinal coupling of the 1’ methylene (δH 3.28, d, 
J=7.0 Hz, δC 29.8) with a vinyl proton (δH 5.24, t, J=7.0 Hz, δC 122.4), together with 
resonances from deshielded methines (δH 5.07, 5.09, 5.25), five allylic methylenes 
(complex multiplet between δH 2.02 and 2.44) and four vinyl methyls (δH 1.65, 1.73, 1.75, 
1.65).76,79 It quickly became apparent that the unique aspects on the terpene chain were the 
presence of a deshielded methine (δH 5.50, δC 131.1) at C10’, a deshielded methylene (δH 
4.27, δC 58.4) at C20’ and the secondary alcohol methine (δH 4.16, δC 77.1) at C12. HMBC 
NMR correlations were observed from the methine and methylene moieties to the 
secondary alcohol methine (δH 4.16, δC 77.1), which confirmed the unique fragment at 
positions 10’, 11’, 12’ and 20’ of the linear terpene chain moiety (see Figure 4.5). HMBC 
correlations were observed from this methylene doublet (δH  3.28, δC 29.8) to the aromatic 
methines [(δH 6.51, δC 115.6) and (δH 6.49, δC 114.1)], the benzohydroquinone moiety (δC 
149.3 and δH 146.0) and a deshielded aromatic methyl (δH δ 2.14, δC 25.7), thereby linking 
the linear terpene to the hydroquinone moiety. HMBC correlations from the methylene 
Methylene doublet 
H1’ δH 3.12 ppm 
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[(δH 4.27, δC 58.4) to C10’, C11’ and C12’ allowed the primary alcohol to positioned at 
C11’. 
Table 4.1. 1H (500 MHz) and 13C (125 MHz) NMR assignment of  
fallahydroquinone (4.8) in CDCl3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aCarbon assignments based on HSQCAD and DEPT experiments 
bOverlapped signals 
ND = Not Detected 
position δΗ (J in Hz) δca, mult gCOSY gHMBC 
1  146.0 s
2  125.4 s   
3 6.48 d (3.0) 114.1 d 5 1, 4, 5, 1’ 
4  149.3 s   
5 6.51 d (3.0) 115.6 d 3, 7  1, 3, 4, 7 
6  127.8 s   
7 2.18 s 16.1b q 5 1, 5, 6 
1’ 3.28 d (7.0) 29.8 t 2’, 18’ 1, 3, 2’, 3’  
2’ 5.24 t (7.0) 122.4 d 1’, 18’ 1’, 4’, 18’ 
3’  137.3 s   
4’a 2.09 m 39.3b t  3’, 5’, 18’ 
4’b 2.02 m   5’ 
5’ 2.14 m 25.8 t  3’, 4’, 7’ 
6’ 5.07 m 124.2 d 19’ 4’, 5’, 8’, 19’ 
7’  134.7 s   
8’a 2.09 m 39.3b t  19’ 
8’b 2.02 m   7’, 10’ 
9’ 2.16 m 26.0 t 10’ 10’, 11’ 
10’ 5.50 t (7.5) 131.1 d 9’ 8’, 9’, 12’, 20’ 
11’  138.3 s   
12’ 4.16 dd (5.5, 8.0) 77.1 d 13’a 10’, 11’, 13’, 14’, 20’ 
13’a 2.44 m 35.0 t 12’, 13’b  11’, 12’, 14’, 15’ 
13’b 2.24 m  13’a 12’, 15’ 
14’ 5.09 m 119.8 d 16’, 17’ 13’, 16’, 17’ 
15’  135.4 s   
16’ 1.65 s 18.0 q 14’ 14’, 15’, 17’ 
17’ 1.73 s 25.9 q 14’ 14’, 15’, 16’ 
18’ 1.75 s 16.0 q 1’, 2’ 2’, 3’, 4’  
19’ 1.58 s 16.1b q 6’ 6’, 7’, 8’ 
20’ 4.27 d (1.5) 58.4 t  10’, 11’, 12’ 
1’-OH ND    
4’-OH ND    
12’-OH ND    
20’-OH ND    
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Figure 4.5. Fragment A of fallahydroquinone (4.8) showing selected HMBC 
correlations that assembled the unique linear chain fragment. The coloured lines represent 
selected correlations that correspond to fragment A of fallahydroquinone (4.8). 
 
 
A
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4.2.2.2 Fallaquinone 
Fallaquinone (4.9) was immediately recognised to be the quinone analogue of 
fallahydroquinone (4.8) on the basis of the similarity of the 1H NMR spectrum and 13C 
NMR chemical shifts (Table 4.2) of the two samples.  
O
O
(4.9)
CH2OH
OH
 
In particular the presence of the methylene doublet (δH 3.12, δC 27.9) suggested a 
benzoquinone to terpene chain linkage when compared to the known compound 
sargaquinoic acid as illustrated in Figure 4.4. Fallaquinone (4.9) was isolated as a pale 
yellow oil for which high resolution ESIMS established the molecular formula as C27H38O4 
(HRESIMS (Figure 4.6) m/z 425.2691 [M-H]- calcd for C27H37O4, 425.2692), possessing 
nine degrees of unsaturation. The IR spectrum of fallaquinone (4.9) was similar to 
fallahydroquinone (4.8) displaying the presence of hydroxy (3391 cm−1), carbonyl (1653 
cm−1) and olefinic moieties (1463 cm−1).  
 
Figure 4.6. High Resolution ESI (negative mode) mass spectrum of fallaquinone (4.8). 
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The HMBC NMR spectrum further supported the presence of the benzoquinone moiety. 
Key HMBC correlations were observed from the aromatic methine protons at positions 3 
(δH 6.45, bs) and 5 (δH 6.54, bs) to the carbonyl carbons (δC 188.4 and δC 188.2), which are 
characteristic signals of the benzoquinone moiety.80 As already mentioned, fallaquinone 
(4.9) is formed as a result of the oxidation of (4.8) on exposure to air and is therefore more 
than likely an artifact. 68  
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Table 4.2. 1H (500 MHz) and 13C (125 MHz) NMR assignment of fallaquinone (4.9) in 
CDCl3. 
position δΗ (J in Hz) δca, mult gCOSY gHMBC 
1  188.2c s    
2  148.7 s   
3 6.45 bs 132.5 d 1’ 1, 5, 1’ 
4  188.4c s   
5 6.54 bs 133.3 d 7 3, 4, 7 
6  146.1 s   
7 2.05b s  16.3 q 5 1, 5, 6 
1’ 3.12 d (6.5) 27.9 t 2’, 3, 18’ 1, 2, 3, 2’, 3’ 
2’ 5.14 m 118.4 d 1’  
3’  140.2 s    
4’ 2.04b m 39.7b t 5’ 2’, 3’, 5’, 6’, 18’ 
5’ 2.12 m 26.6 t 4’ 4’, 6’, 7’ 
6’ 5.10 m 124.6 d 19’ 4’, 5’, 8’, 19’ 
7’  134.8 s   
8’ 2.05b m 39.7b t 9’, 19’ 6’, 7’, 9’ 
9’ 2.20 m 26.1c t 8’, 10’ 10’, 11’ 
10’ 5.51 t (7.5) 130.7d 9’ 8’, 12’, 20’ 
11’  138.7 s   
12’ 4.16 dd (5.5) 8.0) 77.1 d 13’a, 13’b 10’, 11’, 14’, 20’ 
13’a 2.25 m 35.2 t 12’, 14’ 12’, 14’, 15’ 
13’b 2.43 m  12’  
14’ 5.09 m 120.2 d 13’a, 17’ 13’, 17’, 16’  
15’  135.6 s   
16’ 1.64 s 18.0 q  14’, 15’, 17’ 
17’ 1.72 s 26.2c q 14’ 14’, 15’, 16’ 
18’ 1.62 s 16.4b q 1’ 2’, 3’, 4’ 
19’ 1.59 s 16.4b q 6’, 8’ 6’, 7’, 8’ 
20’ 4.26 d (2.5) 58.8 t  10’, 11’, 12’ 
12’-OH ND    
20’-OH ND    
 
aCarbon assignments based on HSQCAD and DEPT experiments 
bOverlapped signals 
cInterchangeable signals 
ND = Not Detected 
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4.2.2.3 Fallachromenoic acid  
Fallachromenoic acid (4.10) was isolated as the major compound co-occuring in a 
mixture with the minor compound sargaquinoic acid (4.2) in a 3:1 ratio, as was evident in 
the HRESIMS and NMR spectra.  
O
HO
2
44a6
8a
1'
3'
16'
5' 7' 9'
11'
14'
13'15'
17'18'
COOH
Cl
(4.10)
 
The high resolution ESIMS for fallachromenoic acid (4.10) established the molecular 
formula as C27H35ClO4 (457.2149 [M-H]-, calcd for C27H34ClO4, 457.2224), possessing ten 
degrees of unsaturation. The presence of the chlorine was supported by the 3:1 isotopic 
ratio in the mass spectrum. The IR spectrum supported the presence of hydroxy (3400 
cm−1), carbonyl (1689 cm−1) and olefinic moieties (1454 and 1590 cm−1). The 1H and 13C 
NMR spectra of (4.10) displayed chemical shifts typical of a chromene moiety attached to 
terpene chain possessing a carboxylic group76,78. The NMR data for (4.10) was compared 
to the literature data of structurally related sargachromenol (4.11). The distinctive feature 
that differed between compounds (4.10) and (4.11) was the presence of the deshielded 
methine carbon at position 11’ (δH 4.38, δC 66.2 ppm) in the spectrum of (4.10). This was 
consistent with presence of a chlorine substituent at C11’ and the linear chain terminal 
olefinic bond at position 13’ (δH 4.89 and 5.01, δC 66.2) in fallachromenoic acid (4.10).  
O
HO
COOH
2
44a6
8a
1'
3'
16'
5' 7' 9' 11' 14'
13'15'
17'18'
(4.11)
 
The placement of the chlorine moiety at position 11’ was supported by HMBC 
correlations to the deshielded methine at position 11’ (δC 66.2), at which the chlorine is 
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attached, from positions 9’ (δH 2.26, m), 10’ (δH 2.00, t), 14’ (δH 1.81, s) and the double 
bond methylene proton at position 13’a (δH 4.89, m). The position of the linear chain 
terminal at 13’ was evident by the HMBC correlation from position 13’a (δH 4.89, m) to 
11’ (δC 66.2) and 14’ (δC 17.2), and 13’b (δH 5.01, m) to 14’ (δC 17.2) (see Table 4.3).  
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Table 4.3. 1H (500 MHz) and 13C (125 MHz) NMR assignment of  
fallachromenoic acid (4.10) in CDCl3. 
position δH (J in Hz) δc, mult gCOSY gHMBC 
2  78.2 s   
3 5.56 d (9.8) 130.8 d 4 2, 4a 
4 6.24 d (9.8) 123.4 d 3 8a 
4a  121.7 s   
5 6.35 d (2.7) 110.8 d 7 4, 7, 8a 
6  145.3 s   
7 6.50 d (2.7) 118.0 d 5 5, 6 
8  126.3 s   
8a  144.8 s   
1’ 1.67 s 40.7 t 2’ 2, 2’ 
2’ 2.12 m 23.0 t 1’, 3’ 1’, 3’, 4’ 
3’ 5.13 m 125.2 d 2’ 2’ 
4’  132.2 s   
5’ 2.05 m 39.3 t 6’ 6’, 16’ 
6’ 2.56 q (7.5) 28.2 t 5’, 7’ 4’, 5’, 7’, 8’  
7’ 5.89 t (7.6) 143.1 d 6’ 15’ 
8’  134.8 s   
9’ 2.26 t (7.4) 35.2 t 10’ 7’, 8’, 10’, 11’, 15’ 
10’ 2.00 t  (7.4) 36.2 t 9’, 11’  9’, 11’, 12’ 
11’ 4.38 m 66.2 d 10’ 9’, 14’ 
12’  144.5 s   
13’a 4.89 m 114.5 t  11’, 14’ 
13’b 5.01 m  14’ 14’ 
14’ 1.81 s 17.2 q 13’b 11’, 12’, 13’ 
15’  170.1 s   
16’ 1.57 s 16.0 q  3’, 4’, 5’ 
17’ 1.35 s 26.1 q  2, 3, 1’ 
18’ 2.13 s 15.6 q  7, 8, 8a 
6-OH ND    
15’-COOH ND    
 
ND = Not Detected 
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4.2.2.4 Sargachromenol 
The structural analogue of (4.10), sargachromenol (4.11) was also isolated and identified 
on the basis of 1D and 2D NMR data in comparison to the literature and. found to be 
identical in all respects.76,78 This study enabled additional structural characterisation data 
for (4.11) to be  reported for this compound.  
4.2.2.5 Stereochemistry of the meroditerpenoids isolated 
Stereochemical assignment of the double bonds of the meroditerpenoids (4.8) to (4.10) 
was made on the basis of the position of the upfield vinyl methyl resonances in the 13C 
NMR spectrum (δC 16.0−18.0) for these compounds.58,5969,81 The E configuration of the 
double bond at C10’-C11’ in compounds (4.8) and (4.9) was determined by comparison of 
the chemical shifts of the olefinic proton at C10’ and the C9’ methylene protons with those 
reported for E- and Z-2-methyl-2-pentenoic acids.76,82 Owing to the instability and rapid 
decomposition of the meroditerpenoids isolated, attempts to secure the relative or absolute 
configurations for the new compounds (4.8), (4.9) and (4.10) could not be carried out. 
4.2.3 Biosynthesis 
The biosynthesis of meroditerpenoid type compounds is proposed83 to proceed via the 
key intermediate, 2-methyl-6-geranylgeranylbenzoquinol, which is formed via 
condensation of homogentisic acid and geranylgeranyl diphosphate, a reaction catalysed by 
the recently characterised homogentisic acid, geranylgeranyl transferase (HGGT) (see 
Figure 4.7).83 The substrate then undergoes a series of enzyme-catalysed methylations (in 
the case of (4.13), (4.14), and (4.15)) and cyclisations to yield the tocotrienol type 
products.83 This biosynthetic pathway in monocot plants is well understood, and it is 
reasonable to speculate that it may be operating in these species of brown algae.  
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Figure 4.7. The proposed biosynthetic scheme of the meroditerpenoid type of 
compounds.83 
 
R1=H, R2=H  (4.12) 
R1=CH3, R2=CH3 (4.13) 
R1=H, R2=CH3 (4.14) 
R1=CH3, R2=H (4.15) 
R=H     (4.16) 
R=OH  (4.17) 
(4.19) 
(4.18) 
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4.2.4 Previously reported Biological activities  
 
Metabolites produced by the Sargassum spp. have been reported to display a range of 
biological activities. Plastoquinones isolated from the brown alga Sargassum 
micracanthum have been shown to contribute towards the diversity and selectivity in the 
bioactive properties of this genus.68,80,84 Compound (4.4), isolated from Sargassum 
micracanthum, displayed significant antioxidant activity and subsequent investigation of 
various analogues of this compound concluded that the activity was attributable to the 
hydroquinone moiety.68 Compound (4.4) also displayed potent cytotoxic activity against 
Colon 26-L5 cells, however the structure activity relationship and pharmacophore remains 
unknown.68 Compounds (4.5) to (4.7), isolated from Sargassum micracanthum, have also 
been evaluated in a number of assays. It was found that compound (4.5) possessed the 
strongest antioxidant activity, which was again, was attributed to the presence of the 
hydroquinone and phenol moieties.80 In addition it was found that compounds (4.6) and 
(4.7) displayed potent antiviral activity against human cytomegalovirus (HCMV), whereas 
compound (4.5) was virtually inactive in this case.80 Further investigation of the biological 
activities of (4.5) to (4.7) suggested the possibility that these compounds may also be 
future candidates for antiulcer effects and prevention of bone diseases such as 
osteoporosis.68,84 Certain glycerides isolated from the Sargassum species, such as 
compounds isolated from Sargassum carpophyllum, where found to cause morphological 
deformation of Pyricularia oryzae mycelia.74 Such a response is indicative of the presence 
of bioactive substances.74 Steroids isolated from Sargassum carpophyllum resulted in 
similar behaviour in Pyricularia oryzae mycelia and also exhibited potent cytotoxic 
activity against P388 cancer cells.85 Chromenes from other organisms also possess a range 
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of bioactive properties such as anticancer, antimutagenic as well as inhibitory activities 
against various enzymes.71  
4.2.4.1 Biological activity evaluated in this study and comparative assays reported in 
literature 
Extracts of the alga Sargassum fallax were evaluated in a number of biological assays at 
50 mg/mL including against a P388 Murine Leukaemia cell line (antitumour assay), 
against Herpes simplex and Polio viruses (antiviral assays) as well as against a number of 
bacteria and fungi (antimicrobial assays) at the University of Canterbury, Christchurch, 
New Zealand. Moderate antitumour activity was observed for the alga extract (IC50 of 
6,984 ng/mL). In addition, the extract displayed cytotoxic activity against the Herpes 
simplex virus and the Polio virus as well as moderate antimicrobial activity with a zone of 
inhibition detected against Bacillus subtilis. No activity was observed against Eschericha 
coli, Pseudomonas aeruginosa, Candida albicans, Trichophyton mentagrophytes or 
Cladosporium resinae.  
In the evaluation of the bioactivity of the isolated meroditerpenoids, sargaquinoic acid 
(4.2) and sargahydroquinoic acid (4.3) were found to display moderate antitumour activity 
(IC50 of 17 and 14 μM, respectively, when tested at 1 mg/mL in the P388 assay). However 
the impurities present in sargaquinoic acid (4.3) may have affected its antitumour activity 
results. Sargaquinone (4.1), fallahydroquinone (4.8), fallaquinone (4.9), fallachromenoic 
acid (4.10) and sargachromenol (4.11) displayed lower antitumour activities (IC50 of 32 
μM for (4.1) and >27-29 μM for (4.8)-(4.10) when tested at 1 mg/mL in the P388 assay). 
Sargaquinoic acid (4.2) and sargahydroquinoic acid (4.3) were evaluated for antimicrobial 
activity and displayed only weak activity against Bacillus subtilis.  
Previously, sargaquinoic acid (4.2) and sargachromenol (4.11) were reported to be 
neuroactive substances that significantly promote neurite outgrowth and support the 
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survival of neuronal cells.86,87 Also, sargaquinoic acid (4.2) and sargachromenol (4.11) in 
combination with UVB, demonstrated apoptotic effects, suggesting their potential use as 
therapeutic agents against hyperproliferative diseases such as psoriasis.88  
 
In comparision to the previously investigated Japanese sample of Sargassum tortile 
reported a series of meroterpenoid chromenes with similar structures (sargaol (5), 
sargadiol-I (6) and sargadiol-II (7), along with a related meroditerpenoid benzoquinone 
(hydroxysargaquinone (8)), was isolated.83 Sargaol (4.16), sargadiol-I (4.17) and sargadiol-
II (4.18) have been reported to show mild cytotoxicity (ED50 of ~14-20 mg/mL) against 
P388 lymphocytic leukemia cells, similar to the extract of S. fallax studied. 
Hydroxysargaquinone (4.19) showed significant cytotoxicity with a reported ED50 of 0.7 
mg/mL.83 The compounds isolated from S. fallax are structurally related to the compounds 
isolated from S. tortile and reasons for the discrepancies can only be speculated.  
Every effort was made to evaluate the biological activity for the isolated 
meroditerpenoids as rapidly as possible. Given their instability, it is possible that the actual 
activity could in fact be greater than that found during this study and may have been 
similar to the compounds isolated (see Figure 4.7) from Sargassum tortile.  
As a result of this investigation of the marine brown alga S. fallax, the biological 
evaluation (antitumour and some antimicrobial activities) of the meroditerpenoids (4.2), 
(4.3), (4.8), (4.9), (4.10) and (4.11) have provided further information into the bioactivity 
of these secondary metabolites in relation to the previously reported bioactivities for the 
related structural analogues (4.1)-(4.7). 
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4.3 Phytochemical Investigation of Unidentified Sargassum species  
 
The brown alga, unidentified Sargassum sp. was collected on the 3rd January 2003 from 
Port Phillip Bay, Victoria, Australia. The alga was identified to genus level by Dr Gerald 
Kraft (Honorary Principal Fellow), School of Botany, University of Melbourne, Australia. 
A voucher specimen designated the code 2003-06 and is deposited at the School of 
Applied Sciences RMIT University. The biological profiling of specimen 2003-06 
indicated that the crude extract displayed moderate antitumour activity (IC50 of 168,632 
ng/mL @ 50 mg/mL) as well as moderate antiviral and antifungal activities.  
A chemotaxonomic profiling study of the brown alga was undertaken and this resulted in 
δ-tocotrienol (3.15) (15 mg, 0.15%) being isolated once again (See Chapter 3.3). A 
similar purification approach was adopted for this specimen (see Scheme 4.2) and the 
resulting DCM extract of Sargassum sp. (2003-06) was fractionated by silica flash 
chromatography (20% stepwise elution). The second fraction, which eluted with 80:20 n-
hexane/DCM, was chromatographed on Sephadex LH-20 (100% MeOH). Subsequent 
fractions were purified using reversed phase HPLC, which afforded δ-tocotrienol (3.15) 
and a suspected linear diterpenoid designated the fraction code PR6 7.1. δ-tocotrienol 
(3.15) was also isolated from Cystophora siliquosa (2003-08) by another member of the 
MATNAP research group, where it was identified as the principal component.  In contrast, 
(3.15) was found to be only a minor compound in the unidentified Sargassum sp. (2003-
06) studied in this project. 
The above studies suggested that since δ-tocotrienol has been identified in many brown 
algae of both the Cystophora and Sargassum genera, it may be a biosynthetic precursor for 
the other co-occurring terpenoids. The hypothesis is supported by the findings reported by 
Amico.33 
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5.  Experimental 
5.1 General Experimental Details 
All organic solvents used were Analytical Reagent grade, UV Spectroscopic or HPLC 
grades with milli-Q water also being used. Optical rotations were carried out using a 1.2 
mL cell on a Jasco DIP-1000 digital polarimeter, set to the Na 589 nm wavelength. UV/Vis 
spectra were recorded on a Varian Cary 50 Bio Spectrophotometer, using EtOH. In 
addition, a UV profile was obtained from the HPLC (PDA detection) by extraction of the 
2D contour plot. IR spectra were recorded as a film using a NaCl disk on a Perkin-Elmer, 
Spectrum One FTIR Spectrometer. 1H (500 MHz) and 13C (125 MHz) and single 
irradiation nOe NMR spectra were acquired in CDCl3 on a 500 MHz Varian INOVA 
Spectrometer with referencing to solvent signals (δ 7.26 and 77.0 ppm). Two-dimensional 
NMR experiments recorded included gCOSY, gHSQCAD and gHMBC experiments. ESI 
mass spectra were obtained on a Micromass Platform II mass spectrometer equipped with a 
LC-10AD Shimadzu solvent delivery module (50% CH3CN/H2O at a flow rate of 0.1 
mL/min) in both the positive and negative ionisation modes using cone voltages between 
20 V and 30 V. High Resolution ESI mass spectrometry was carried out on either an 
Agilent G1969A LC- Time-of-Flight (TOF) system (ESI operation conditions of 8 L/min 
N2, 350 degrees drying gas temperature and 4000 V capillary voltage) equipped with an 
Agilent 1100 Series LC solvent delivery module (50% MeOH/H2O with 0.1 % acetic acid 
at a flow rate of 0.3 mL/min) or an Agilent 6200 Series TOF system (ESI operation 
conditions of 8 L/min N2, 350 degrees drying gas temperature and 4000 V capillary 
voltage) equipped with an Agilent 1200 Series LC solvent delivery module (100% MeOH 
at a flow rate of 0.3 mL/min) in either the negative and positive ionisation modes (in all 
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cases the instruments were calibrated using the ‘Agilent Tuning Mix’ using purine as the 
reference compound). TLC was performed on pre-coated aluminium backed silica TLC 
plates (Merck™ silica gel 60 F254) using the solvent system 65:25:4 (CHCl3:MeOH:H2O), 
visualised at 254 and 365 nm and further developed using A: iodine vapour and B: a 
ninhydrin dip consisting of 0.3 g ninhydrin in 100 mL of n-butanol and 3 mL acetic acid. 
Silica flash chromatography was carried out with Merck™ silica gel (60 mesh) using 
nitrogen and a 20% stepwise solvent elution from 100% n-hexane to 100% DCM to 100% 
EtOAc and finally to 100% MeOH. Gel permeation chromatography was performed using 
Sephadex LH-20 (Sigma™) using 100% MeOH as the eluant. All analytical HPLC 
analyses were performed on a Dionex P680 solvent delivery system equipped with a 
PDA100 UV detector (operated using “Chromeleon” software). Analytical HPLC analyses 
were run using either a gradient method (0-2 min 10% CH3CN/H2O; 14-24 min 75% 
CH3CN/H2O; 26-30 min 100% CH3CNand 32-40 min 10% CH3CN/H2O) or an isocratic 
methods such as (either 60% CH3CN/H2O or 65% CH3CN/H2O for Chapter 3 or 80% 
CH3CN/H2O or 85% CH3CN/H2O for Chapter 4) on a Phenomenex Prodigy ODS (3) C18 
100Å 250 × 4.6 (5 μ) and on a Phenomenex Luna ODS (3) C18 100Å 250 × 4.6 (5 μ) 
column at a flow rate of 1.0 mL/min. All semi-preparative HPLC was carried out on a 
Varian Prostar 210 (Solvent Delivery Module) equipped with a Varian Prostar 335 PDA 
detector using STAR LC WS Version 6.0 software using an isocratic method (60% or 65% 
CH3CN/H2O (for Chapter 3 purifications) or 85% CH3CN/H2O (for Chapter 4 
purifications) and a Phenomenex Prodigy ODS (3) 100Å C18 250 × 10 (5 μ) column at a 
flow rate of 3.5 mL/min. 
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5.1.1 Biological evaluation and details of assays 
Extracts of the algae were evaluated at 50 mg/mL in a number of biological assays 
including against a P388 Murine Leukaemia cell line (antitumour assay), against Herpes 
simplex and Polio viruses (antiviral assays) as well as against a number of bacteria and 
fungi (antimicrobial assays) at the University of Canterbury, Christchurch, New Zealand.  
5.1.1.1 Antitumour assay (P388 murine leukaemia cell line) 
For the antitumour assay a two-fold dilution series of the crude extracts as well as 
compounds were incubated for 72 hours with P388 (Murine Leukaemia) cells. The 
concentration of sample required to reduce the P388 cell growth by 50% (comparative to 
control cells) was determined using the absorbance values obtained when the yellow dye 
MTT tetrazolium is reduced by healthy cells to the purple coloured MTT formazan and is 
expressed as an IC50, in ng/mL. 
5.1.1.2 Antiviral assays (Herpes simplex virus and Polio virus) 
The crude extract was pipetted onto 6 mm diameter filter paper discs and the solvent 
evaporated. The disc was then placed directly onto BSC-1 cells (African Green Monkey 
kidney), infected with either the DNA Herpes simplex virus type 1 (ATCC VR-733) or the 
RNA Polio virus type 1 (ATCC VR-192) and then incubated. The assays were examined 
after 24 hours using an inverted microscope for the size of antiviral or viral inhibition 
and/or cytotoxic zones and the type of cytotoxicity. Recently, the University of Canterbury 
phased out these antiviral assays. 
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5.1.1.3 Antimicrobial assays 
A standardised inoculum was prepared by transferring a loop of bacterial/fungal cells, from 
a freshly grown stock slant culture, into a 10 mL vial of sterile water. This was vortexed 
and compared to a 5% BaCl2 in water standard to standardise the cell density. This gave a 
cell density of 108 colony-forming units per mL. 10 mL of the standardised inoculum was 
then added to 100 mL of Mueller Hinton or Potato dextrose agar and mixed by swirling, 
giving a final cell density of 107 colony-forming units per mL. 5 mL of this was poured 
into sterile 85 mm petri dishes. The suspensions were allowed to cool and solidify on a 
level surface to give a ‘lawn’ of bacteria/fungi over the dish. The crude extracts as well as 
compounds were pipetted onto 6 mm diameter filter paper discs and their solvents 
evaporated. These discs were then placed onto the prepared seeded agar dishes (with 
appropriate solvent and positive controls) and incubated. Active antimicrobial samples 
displayed a zone of inhibition outside the disc, which was measured in millimetres as the 
radius of inhibition for each bacteria/fungi. The six organisms were Eschericha coli (G-ve 
ATCC 25922), Bacillus subtilis (G+ve ATCC 19659) and Pseudomonas aeruginosa (G-ve 
ATCC27853) for the bacteria and Candida albicans (ATCC 14053), Trichophyton 
mentagrophytes (ATCC 28185) and Cladosporium resinae for the fungi. Since the 
completion of these studies the University of Canterbury has phased out these 
antimicrobial assays. 
 
Chapter 5. Experimental 
 
________________________________________________________________________________________________ 
99 
5.2 Chapter 3 Experimental 
δ-tocotrienol (3.15) 
Isolated as a pale yellow oil; UV profile from HPLC 
(CH3CN/H2O) 290 nm; IR was previously reported;49 1H 
NMR (300 MHz, CDCl3) 6.51 (1H, d, J= 3.0 Hz, H-7), 
6.42 (1H, d, J= 3.0 Hz, H-5), 5.14 (3H, m, H-3’, H-7’ 
and H-11’)*, 2.72 (2H, t, J= 6.8 Hz, H-2’), 2.16 (3H, s, H-8b), 2.00 (6H, m, H-6’, H-4 and 
H-10’)*, 1.79 (2H, m, H-3), 1.72 (3H, s, H-13’), 1.62 (9H, s, H-4’a, H-8’a and H-12’a)*, 
1.60 (6H, m, H-1’, H-5’ and H-9’)*; 1.28 (3H, s, H-2a); 13C (75 MHz, CDCl3) 147.9 (C, C-
6), 145.9 (C, C-8a), 135.1 (C, C4’), 134.9 (C, C-8’), 131.2 (C, C-12’), 127.3 (C, C-4a), 
124.2 (CH, C-11’), 124.4 (CH, C-3’), 124.3 (CH, C-7’), 121.2 (C, C-8), 115.7 (CH, C-7), 
112.6 (CH, C-5), 75.3 (C, C-2), 39.7 (CH2, C1’, C5’ and C9’)*, 31.4 (CH2, C-3), 26.8 
(CH2, C-10’), 26.6 (CH2, C-6’), 25.7 (CH3, C-13’), 24.0 (CH3, C-2a), 22.5 (CH2, C-2’), 
22.2 (CH2, C-4), 17.7 (CH3, C-12’a), 16.1 (CH3, C-8’a), 16.0 (CH3, C-4’a), 15.9 (CH3, C-
8b); GC-EI/MS m/z (relative intensity) 396 (35) [M]+, 192 (24), 177 (62) [C11H13O2]+, 137 
(97) [C8H9O2]+, 69 (94), 41 (59). 
* Overlapped signals 
 
 
(3.15)
O
OH6
8
4a
22'
4'a
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Compound (3.19) [(E)-8-((1R,3S)-3-hydroxy-2,2-dimethyl-6-methylenecyclohexyl)-6-
methyloct-5-en-2-one]: (major compound) 
Isolated as a colourless viscous oil in a mixture with 
compound (3.20) in a 3:1 ratio; UV profile from HPLC 
(CH3CN/H2O) 210 nm; IR has been previously 
reported15; Partial 1H NMR (500 MHz, CDCl3) 
extrapolated from a mixture of (3.19) and (3.20) δ 5.04 (1H, t, J = 7.0 Hz, H-5), 4.86 (1H, 
s, H-7’a), 4.58 (1H, s, H-7’b), 3.41, (1H, dd, J = 4.5, 10.0 Hz, H-3’), 2.46 (2H, m, H-
3), 2.26 (4H, q,  J = 7.5 Hz, H-4), 2.14 (6H*, s, H-1), 1.61 (3H, s, H-9), 1.02 (3H, s, H-8’), 
0.71 (3H, s, H-9’); 13C NMR has been previously reported15; ESIMS (positive mode) m/z 
279 [M+H]+. 
* Signal overlapped with methyl of compound (3.20) and 3’-OH not detected. 
 
Compound (3.20) [(E)-8-(1R,3S)-3-hydroxy-2,2-dimethyl-6-methylenecyclohexyl)-6-
methyloct-5-en-2-one]: (minor compound) 
Isolated as a colourless viscous oil in a mixture with 
compound (3.19) in a 1:3 ratio; IR has been previously 
reported15; UV profile from HPLC (CH3CN/H2O) 210 
nm; Partial 1H NMR (500 MHz, CDCl3) extrapolated from a mixture of (3.20) and (3.19) 
δ 5.23 (1H, m, H-5’), 5.09 (1H, t, J = 6.8 Hz, H-5), 3.46, (1H, dd, J = 5.5, 8.0 Hz, H-3’), 
2.47 (2H, m, H-3), 2.32 (4H, dt, J = 5.0, 13.0 Hz, H-8), 2.14 (6H*, s, H-1), 1.70 (3H, bs, H-
9), 1.63 (3H, s, H-7’), 0.96 (3H, s, H-8’), 0.82 (3H, s, H-9’); 13C NMR has been previously 
reported15; ESIMS (positive mode) m/z 279 [M+H]+ 
.* Signal overlapped with methyl of compound (3.19) and 3’-OH not detected.  
Compound (3.21) (5E)-8-((S)-3-hydroxy-2,2,6-trimethylcyclohex-1-enyl)-6-methyloct-5-
en-2-one; 
HO
O
1
4
8'
7'
1'3' 7
9  
HO
O
1
4
8'
7'
1'3' 7
9  
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HO
O
1
4
8'
7'
1'3' 7
9  
Isolated as a colourless volatile oil; due to its volatility an optical rotation of this 
compound could not be carried out as most of the mass was lost upon drying; UV (EtOH) 
λmax (log ε) 205 nm (4.06); IR has been previously reported15; 1H NMR (500 MHz, CDCl3) 
δ 5.12 (1H, t, J = 7.2 Hz, H-5), 3.50 (1H, m, H-3’),  2.47 (2H, t, J = 7.5 Hz, H-3), 2.27 
(2H, q, J = 7.0 Hz, H-4),  2.15 (3H, s, H-1), 2.04 (4H, m, H-8 and H-5’)*,  2.01 (2H, m, H-
7), 1.80 (1H, m, H-4’a), 1.68 (1H, m, H-4’b), 1.66 (3H, s, H-9), 1.61 (3H, s, H-7’),  1.07 
(3H, s, H-8’), 1.01 (3H, s, H-9’); 13C (125 MHz, CDCl3) 209.0 (C, C-2), 137.4 (C, C-6), 
135.6 (C, C-1’), 126.6 (C, C-6’), 122.3 (CH, C-5), 76.3 (CH, C-3’), 43.9 (CH2, C-3), 40.2 
(C, C-7)*, 40.2 (CH2, C-2’)*, 30.1 (CH3, C-1), 29.9 (CH2, C-5’), 28.1 (CH2, C-8), 26.6 
(CH2, C-4’), 26.5 (CH3, C-8’), 22.6 (CH2, C-4), 21.9 (CH3, C-9’), 19.7 (CH3, C-7’) and 
16.4 (CH3, C-9); due to its volatility a mass spectrum of this compound could not be 
carried out as most of the mass was lost upon drying. 
* Overlapped signals and 3’-OH not detected. 
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Compound (3.22) (5E,9E)-13-hydroxy-6,10,14-trimethylpentadeca-5,9,14-trien-2-one 
 
Colourless viscous oil; [α]21D -36 (c 0.02, CHCl3); 
UV (EtOH) λmax (log ε) 205 nm (3.72); IR has been 
previously reported15; 1H NMR (500 MHz, CDCl3) 
δ 5.13 (1H, t, J = 7.0 Hz, H-9), 5.07 (2H, t,  J = 7.0 Hz, H-5), 4.94 (1H, bs, H-16a), 4.84 
(1H, d, J = 1.24 Hz, H-16b), 4.04 (2H, t, J = 6.3 Hz, H-13), 2.60 (1H, bs, 13-OH), 2.46 
(2H, t, J = 7.5 Hz, H-3), 2.26 (2H, q, J = 7.0 Hz, H-4), 2.14 (3H, s, H-1), 2.08 (2H, m, H-
8), 2.02 (2H, m, H-11), 1.99 (2H, m, H-7), 1.73 (3H, s, H-15), 1.63 (2H, m, H-12), 1.61 
(6H, s, H-17 and H-18)*; 13C (125 MHz, CDCl3) 208.3 (C, C-2), 147.8 (C, C-14), 136.6 (C, 
C-10), 135.8 (C, C-6), 124.8 (CH, C-9), 123.0 (CH, C-5), 111.3 (CH2, C-16), 75.8 (CH, C-
13), 43.9 (CH2, C-3), 39.8 (CH2, C-7), 35.9 (CH2, C-11), 33.2 (CH2, C-12), 29.8 (CH3, C-
1), 26.5 (CH2, C-8), 22.6 (CH2, C-4), 18.0 (CH3, C-15), 16.1 (CH3, C-17)*, 16.1 (CH3, C-
18)*; ESIMS (positive mode) m/z 279 [M+H]+, 261 [(M+H)-H2O]+. 
* Overlapped signals 
 
 
 
O
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5
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Compound (3.23) (R,5E,9E)-13,14-dihydroxy-6,10,14-trimethylpentadeca-5,9-dien-2-one 
Isolated as a colourless viscous oil; [α]25D -13.9 (c 
0.094, CHCl3); UV (EtOH) λmax (log ε) 207 nm 
(3.82); IR has been previously reported15; 1H NMR 
(500 MHz, CDCl3) δ 5.16 (1H, t, J = 7 Hz, H-9),  5.07 (2H, dt, J = 7 Hz, H-5),  3.36 (1H, 
dd, J = 1.5, 10.5 Hz, H-13),  2.47 (2H, t, J = 7.5 Hz, H-3), 2.27 (2H, m, H-4), 2.23 (1H, m, 
H-11a), 2.13 (3H, s, H1), 2.09 (3H, m, H-8 and H-11b)*, 2.00 (2H, t, J = 7.5 Hz, H-7), 1.60 
(7H, m, H-12a, H-17 and H-18)*, 1.41 (1H, m, H-12b), 1.20 (3H, s, H-15),  1.16 (3H, s, H-
16); 13C (125 MHz, CDCl3) δ 209.2 (C, C-2), 136.1 (C, C-6), 134.9 (C, C-10), 124.8 (CH, 
C-9), 122.8 (CH, C-5), 78.1 (CH, C-13), 72.9 (C, C-14), 43.7 (CH2, C-3), 39.5 (CH2, C-7), 
36.7 (CH2, C-11), 29.9 (CH3, C-1), 29.6 (CH2, C-12), 26.4 (CH2, C-8), 26.3 (CH3, C-15), 
23.3 (CH3, C-16), 22.4 (CH2, C-4), 15.9 (CH3, C-17 and C-18)*; ESIMS (negative mode) 
m/z 295 [M-H]-; GC-EI/MS m/z (relative intensity) 281 (9) [M+- CH3]+, 237 (6), 207 (13) 
[C14H23O]+, 201 (21), 177 (7), 161 (23), 134 (16), 121 (18), 107 (24), 95 (41), 83 (76), 71 
(16) [C4H7O]+ 67 (35), 55 (24).  
* Overlapped signals and 13-OH not detected. 
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Compound (3.24) (5E,9E,13Z)-15-hydroxy-6,10,14-trimethylpentadeca-5,9,13-trien-2-one 
Isolated as a colourless viscous oil; UV (EtOH) λmax 
(log ε) 205 nm (3.64); IR (film) νmax 3402, 2918, 1713, 
1463, 1381, 1216 cm-1; 1H NMR (500 MHz ,CDCl3) 
δ 5.27 (1H, t, J = 7.5 Hz, H-13), 5.08 (1H, m, H-9), 5.07 
(1H, m, H-5), 4.11 (2H, s, H-16), 3.15 (1H, bs, 16-OH), 2.46 (2H, t, J = 7.0 Hz, H-3), 2.26 
(2H, q, J = 7.0 Hz, H-4), 2.14 (3H, s, H-1), 2.13 (2H, m, H-12), 2.07 (2H, q, J = 7.0 Hz, 
H-8), 1.98 (2H, m, H-11), 1.97 (2H, m, H-7), 1.79 (3H, s, H-15), 1.61 (3H, s, H-18), 1.59 
(3H, s H-17); 13C (125 MHz, CDCl3) 209.3 (C, C-2), 136.7 (C, C-6), 135.1 (C, C-10), 
134.6 (C, C-14), 128.6 (CH, C-13), 124.9 (CH, C-9), 122.9 (CH, C-5), 61.8 (CH2, C-16), 
44.1 (CH2, C-3), 39.9 (CH2, C-7 and C-11)*, 30.2 (CH3, C-1), 26.7 (CH2, C-8), 26.5 (CH2, 
C-12), 22.6 (CH2, C-4), 21.6 (CH3, C-15), 16.3 (CH3, C-17), 16.2 (CH3, C-18); ESIMS 
(positive mode) m/z 279 [M+H]+; HRESIMS m/z 279.2311 [M+H]+ (calcd for C18H33O3, 
279.2324) and m/z 301.2141 [M+Na]+ (calcd for C18H32O3Na, 301.2143). 
* Overlapped signals 
 
 
 
OCH2OH  
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Moniliforminol A (3.25) 
Isolated as a colourless viscous oil; [α]25D +12.75 (c 
0.032, CHCl3); UV (EtOH) λmax (log ε)  200 nm 
(3.96); IR (film) νmax 3401, 2925, 1709, 1589, 1458, 
1347, 1309, 1162 cm-1; 1H NMR (500 MHz, CDCl3) and 13C (125 MHz, CDCl3) see Table 
3.1; ESIMS (positive mode) m/z 318.9 [M+Na]+; HRESIMS m/z 319.2252 [M+Na]+ (calcd 
for C18H32O3Na, 319.2249); GC-EI/MS m/z (relative intensity) 281 (1) [M+- CH3]+, 211 
(3), 182 (6), 157 (12) [C9H17O2]+, 140 (7), 115 (21), 98 (20), 83 (16), 73 (12), 71 (2) 
[C4H7O]+.  
 
 
 
Moniliforminol B (3.26) 
Isolated as a colourless viscous oil; [α]25D -8.0 (c 
0.03, CHCl3); UV (EtOH) λmax (log ε) 200 nm (4.00); 
IR (film) νmax 3369, 2927, 1714, 1589, 1456, 1371, 
1347, 1307, 1163 cm-1; 1H NMR (500 MHz, CDCl3) and 13C (125 MHz, CDCl3) see Table 
3.2; ESIMS (positive mode) m/z 318.9 [M+Na]+; HRESIMS m/z 319.2251 [M+Na]+ (calcd 
for C18H32O3Na, 319.2249). GC-EI/MS m/z (relative intensity) 296 (4), 264 (39), 253 (1) 
[C16H29O2]+, 235 (9), 222 (12), 180 (11), 166 (11), 157 (3) [C9H17O2]+, 137 (15), 123 (20), 
111 (20) [C7H11O]+, 96 (46), 83 (50), 67 (50).  
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Compound (3.27) (R,5E,9E)-13-hydroxy-14-methoxy-6,10,14-trimethylpentadeca-5,9-
dien-2-one 
colourless viscous oil; [α]25D -46.8 (c 0.016, 
CHCl3); UV (EtOH) λmax (log ε) 201 nm (3.52); 
UV profile from HPLC (CH3CN/H2O) 210 nm; 
IR (film) νmax 3468, 2928, 1716, 1445, 1362, 1151, 1078 cm-1; 1H NMR (500 MHz, 
CDCl3) and 13C (125 MHz, CDCl3) see Table 3.3; ESIMS (positive mode) m/z 333.3 
[M+Na]+; HRESIMS m/z 333.2401 [M+Na]+ (calcd for C19H34O3Na, 333.2406). 
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5.3 Chapter 4 Experimental 
Sargaquinone (4.1) 
Isolated as a pale yellow unstable oil; UV 
λ EtOHmax   (log ε) 255 nm (4.2); IR (film) νCHCl3max  
cm-1: 3392, 2926, 2854, 1715, 1653, 
1455, 1378, 1292; 1H NMR (500 MHz, 
CDCl3) 6.47 (1H, dq, J = 1.5, 3.0 Hz, H-3), 6.55 (1H, dq, J = 1.5, 3.0 Hz H-5), 2.06 (3H, d, 
J = 1.5 Hz, H-7), 3.13 (2H, d, J = 6.5 Hz, H-1’), 5.16 (1H, t, J = 7.0 Hz, H-2’), 2.03 (6H, 
m, H-4’, H-8’ and H-12’)*, 2.08 (2H, m, H-5’, H-9’ and H-13’)*, 5.11 (3H, m, H-6’, H-10’ 
and H-14’)*, 1.69 (3H, s, H-16’), 1.59 (3H, s, H-17’ and H-20’)*, 1.61 (3H, s, H-18’ and H-
19’)*; 13C (125 MHz, CDCl3) 187.8 (C, C-1), 148.9 (C, C-2), 132.4 (CH, C-3), 188.3 (C, 
C-4), 133.4 (CH, C-5), 146.0 (C, C-6), 16.2 (CH3, C-7), 27.9 (CH2, C-1’), 118.3 (CH, C-
2’), 139.8 (C, C-3’), 39.7 (CH2, C-4’, C8’ and C12’)*, 26.5 (CH2, C-5’, C-9’ and C13’)*, 
124.4 (CH, C-6’ and C14’)*, 134.7 (C, C-7’ and C-11’)*, 26.5 (CH2, C-9’), 124.2 (CH, C-
10’), 131.1 (C, C-15’), 25.6 (CH3, C-16’), 17.8 (CH3, C-17’), 16.2 (CH3, C-18’, C-19’ and 
C-20’)*. In the time it took to acquire the mass spectrum for sargaquinone (1) it had 
degraded.  
* Overlapped signals 
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Sargahydroquinoic acid (4.2) 
Isolated as a pale yellow unstable oil; 
λ EtOHmax   (log ε) 251 (5.05); IR (film) νCHCl3max  
cm-1: 3418, 2922, 2854, 1686, 1670, 
1654, 1614, 1439, 1377, 1294, 1260, 
1194; 1H NMR (500 MHz, CDCl3): δ 6.51 (1H, d, J = 3.0 Hz, H-5), δ 6.48 (1H, d, J = 3.0 
Hz, H-3), 5.95 (1H, t, J = 7.0 Hz, H-10’), 5.26 (1H, t, J = 7.0 Hz, H-2’), 5.11 (1H, t, J = 6.5 
Hz, H-6’), 5.09 (1H, t, J = 6.0 Hz, H-14’), 3.28 (2H, d, J = 7.0 Hz, H-1’), 2.57 (2H, q, J = 
7.5 Hz, H-9’), 2.26 (2H, t, J = 7.0 Hz, H-12’), 2.17 (3H, s, H-7), 2.13 (4H, m, H-5’ and H-
13’)*, 2.07 (4H, m, H-4’ and H-8’)*, 1.74 (3H, s, H-18’), 1.67 (3H, s, H-17’), 1.59 (3H, s, 
H-16’), 1.58 (3H, s, H-19’), COOH†, 1-OH†, 4-OH†; 13C NMR (125 MHz, CDCl3) 171.7 
(C, C-20’), 149.0 (s, C-4), δ 146.2 (C, C-1), 144.5 (CH, C-10’), 138.0 (C, C-3’), 134.8 (C, 
C-7’),  132.2 (C, C-15’), 130.9 (C, C-11’),  127.6 (C, C-2), 125.5 (C, C-6), 124.2 (CH, C-
6’), 123.5 (CH, C-14’), 121.8 (CH, C-2’), 115.5 (CH, C-5), 114.0 (CH, C-3), 39.5 (CH2, C-
4’), 39.1 (CH2, C-8’), 34.6 (CH2, C-12’), 29.9 (CH2, C-1’), 28.3 (CH2, C-13’), 27.8 (CH2, 
C-9’), 26.0 (CH2, C-5’), 25.6 (CH3, C-17’), 17.7 (CH3, C-16’), 16.2 (CH3, C-18’), 16.1 
(CH3, C-7), 16.0 (CH3, C-19’). In the time it took to acquire the mass spectrum for 
sargahydroquinoic acid (2) it had converted to sargaquinoic acid (3).  
* Overlapped signals. 
† Not detected. 
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Sargaquinoic acid (4.3) 
Isolated as a pale yellow unstable oil; UV 
λ EtOHmax   (log ε) 252 nm (4.28); IR (film) νCHCl3max  
cm-1: 3337, 2925, 2854, 1686, 1655, 1439, 
1377, 1293; 1H NMR (500 MHz, CDCl3): δ 
6.54 (1H, dq, J = 1.5, 2.5 Hz, H-5), δ 6.46 (1H, dq, J = 1.5, 2.5 Hz, H-3), 5.95 (1H, t, J = 
7.0 Hz, H-10’), 5.14 (1H, m, H-2’), 5.11 (1H, m, H-6’), 5.09 (1H, m, H-14’), 3.12 (2H, d, J 
= 7.0 Hz, H-1’), 2.58 (2H, d, J = 7.0 Hz, H-9’), 2.26 (2H, t, J = 7.0 Hz, H-12’), 2.11 (2H, 
m, H-13’), 2.09 (2H, m, H-5’), 2.06 (4H, m, H-4’ and H-8’)*, δ 2.05 (3H, s, H-7), 1.67 (3H, 
s, H-17’), 1.61 (3H, s, H-18’), 1.59 (3H, s, H-19’), 1.58 (3H, s, H-16’), COOH†; 13C NMR 
(125 MHz, CDCl3) δ 188.0 (C, C-1), 187.9 (C, C-4), 171.8 (C, C-20’); 148.5 (C, C-2), 
145.9 (C, C-6), 144.4 (CH, C-10’), 139.8 (C, C-3’), 134.6 (C, C-7’), 133.1 (CH, C-5), 
132.2 (CH, C-3), 132.1 (C, C-15’), 130.9 (C, C-11’), 124.4 (CH, C-6’), 123.5 (CH, C-14’), 
117.9 (CH, C-2’), 39.5 (CH2, C-4’), 39.0 (CH2, C-8’), 34.6 (CH2, C-12’), 28.2 (CH2, C-9’), 
27.5 (CH2, C-1’), 27.8 (CH2, C-13’), 26.3 (CH2, C-5’), 25.6 (CH3, C-17’), 17.7 (CH3, C-
16’), 16.1 (CH3, C-7), 16.0 (CH3, C-18’), 15.9 (CH3, C-19’); ESIMS (negative mode) m/z 
423 [M-H]-. 
* Overlapped signals. 
† Not detected. 
 
 
3'
18'
11'
16'
1
7
5
O
O
COOH
9' 13'
 
Chapter 5. Experimental 
 
________________________________________________________________________________________________ 
110
Fallahydroquinone (4.8) 
Isolated as a pale yellow unstable oil; 
[α]25D +54.9° (c 0.08, CHCl3); UV λ EtOHmax   
(log ε) 256 nm (4.0); IR νCHCl3max  cm−1: 
3368, 2963, 2920, 2859, 1652, 1614, 
1461, 1441, 1377, 1315, 1196, 1144; 1H and 13C NMR spectroscopic data, see Table 4.1; 
ESIMS (positive ion mode) m/z 451 [M+Na]+ and 467 [M+K]+; ESIMS (negative ion 
mode) m/z 427 [M-H]-; HRESIMS m/z 451.2812 [M+Na]+; calcd for C27H40O4Na, 
451.2824. 
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Fallaquinone (4.9) 
Isolated as a pale yellow unstable oil; [α]25D -
12.5° (CHCl3, c 0.0760); UV λ EtOHmax   (log ε) 255 
nm (3.8); IR (film) νCHCl3max  cm-1: 3390, 2951, 
1667, 1589, 1463, 1377; 1H and 13C NMR spectroscopic data, see Table 4.2; ESIMS 
(negative mode) m/z 425.3 [M-H]-; 461.3 [M+Cl]-; HRESIMS m/z 425.2691 [M-H]-; calcd 
for C27H37O4, 425.2692. 
 
 
 
Fallachromenoic acid (4.10)  
Isolated as a pale yellow unstable oil; 
[α]25D -73.8° (CHCl3, c 0.0280); UV λ EtOHmax   
(log ε) 340 nm (3.0); IR (film) νCHCl3max  cm-1: 
3401, 2925, 2853, 1689, 1588, 1455, 1348, 1377; 1H and 13C NMR spectroscopic data, see 
Table 4.3; ESIMS (negative mode) m/z 457.0 [M-H]-; HRESIMS m/z 457.2149 [M-H]+; 
calcd for C27H34ClO4, 457.2224. 
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Sargachromenol (4.11) 
Isolated as a pale yellow unstable oil; 
[α]25D -23.7° (CHCl3, c 0.0720);  UV λ EtOHmax   
(log ε) 330 nm (3.1); IR (film) νCHCl3max  cm-1: 
3401, 2964, 2924, 2853, 1683, 1652, 
1462, 1377, 1312, 1256, 1216; 1H NMR (500 MHz, CDCl3) δ 6.50 (1H, d, J = 2.3 Hz, H-
7), 6.35 (1H, d, J = 2.3 Hz, H-5), 6.24 (1H, d, J = 10.0 Hz, H-4), 5.91 (1H, t, J = 7.0 Hz, 
H-7’), 5.56 (1H, d, J = 10.0 Hz, H-3), 5.13 (1H, m, H-3’), 5.09 (1H, m, H-11’), 2.57 (2H, 
q, J = 7.5 Hz, H-6’), 2.11 (5H, m, H-2’, H-10’ and H-18’), 2.05 (2H, m, H-5),1.67 (3H, s, 
H-13’), 1.65 (2H, m, H-1’), 1.58 (3H, s, H-14’), 1.56 (3H, s, H-16’), 1.35 (3H, s, H-17’), 
COOH†; 13C NMR (125 MHz, CDCl3) δ 170.7 (C, C-15’), 77.7 (C, C-2), 130.6 (CH, C-3), 
122.9 (CH, C-4), 121.3 (C, C-4a), 110.3 (CH, C-5), 148.9 (C, C-6), 117.1 (CH, C-7), 126.2 
(C, C-8), 144.7 (C, C-8a), 40.7 (CH2, C-1’), 22.6 (CH2, C-2’), 124.8 (CH, C-3’), 134.4 (C, 
C-4’), 39.1 (CH2, C-5’), 28.1 (CH2, C-6’), 145.4 (CH, C-7’), 130.9 (C, C-8’), 34.7 (CH2, 
C-9’), 27.8 (CH2, C-10’), 123.5 (CH2, C-12’), 132.1 (CH2, C-12’), 25.7 (CH3, C-13’), 17.7 
(CH3, C-14’), 15.5 (CH3, C-16’), 25.9 (CH3, C-17’), 15.8 (CH3, C-18’); ESIMS (negative 
mode) m/z 423 [M-H]-. 
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APPENDIX
 119
The 1H NMR spectrum of Moniliforminol B (3.25) revealing the integration of peaks. 
 
p p m ( f1 )
1 .02 .03 .04 .05 .06 .07 .08 .09 .0
ppm (f1)
1.02.03.04.05.0
3.00
2.08
2.07
1.17
1.98
1.05
1.21
2.95
1.16
1.10
2.36
2.02
3.20
3.23
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The 1H NMR spectrum of Moniliforminol B (3.26) revealing the integration of all peaks. 
 121
The 1H NMR spectrum of Compound (3.27) revealing the integration of all peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ppm (f1)
1.502.002.503.003.504.004.505.00
3.38
2.06
3.13
0.99
1.19
2.32
1.33
1.13
5.96
2.97
0.92
3.26
6.33
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The 1H NMR spectrum of Compound (4.8) revealing the integration of all peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ppm (f1)
1.02.03.04.05.06.07.0
ppm (f1)
2.002.50
1.18
1.65
3.92
1.07
3.33
3.19
2.54
5.93
3.57
3.15
ppm (f1)
3.504.004.505.005.506.006.50
1.00
0.96
1.11
1.03
2.39
2.12
1.23
2.18
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The 1H NMR spectrum of Compound (4.9) revealing the integration of all peaks. 
 
 
 
 
ppm (t1)
4.05.06.07.0
1.40
1.25
2.38
1.76
2.58
2.53
1.66
1.12
ppm (t1)
1.502.00
8.54
2.94
0.95
3.64
3.68
3.92
4.44
1.25
ppm (t1)
1.02.03.04.05.06.07.0
1.40
1.25
2.38
1.76
2.58
2.53
1.66
1.12
8.54
2.94
0.95
3.64
3.68
3.92
4.44
1.25
